TLDRCloud business drives revenue growth and backlog expansionProfit rises as acquisitions influence outlookCash flow strengthens as share repurchases continueGet 3 Free Stock Ebooks SAP stock falls despite strong Q2 cloud revenue and earnings growth. Cloud ERP revenue jumps 25% as cloud backlog reaches €22.9 billion. Free cash flow climbs 27% to €3 billion in the second quarter. Total revenue rises 9% as cloud business offsets software declines. SAP updates 2026 outlook after Dremio and Prior Labs acquisitions. SAP SE (SAP) shares closed at $146.38, down 1.59%, before rising 1.79% to $149.00 in after-hours trading after second-quarter earnings. The software company reported stronger cloud growth, higher profit, and expanding free cash flow despite slower software license sales. The results also reflected continued demand for cloud enterprise products and AI-driven business software.
SAP SE, SAP
Cloud business drives revenue growth and backlog expansion SAP reported current cloud backlog of €22.9 billion during the second quarter. The figure increased 27% year over year and 26% at constant currencies. Moreover, the company said cloud backlog benefited slightly from the Reltio acquisition.
Cloud revenue reached €6.28 billion during the quarter. That result increased 22% from the previous year and 24% at constant currencies. Cloud ERP Suite revenue climbed 25% and 27% at constant currencies.
Cloud and software revenue increased 11% to €8.85 billion. Total revenue rose 9% to €9.88 billion and 11% at constant currencies. Services revenue declined 3% to €1.03 billion, while software license revenue dropped 32% to €131 million.
Software support revenue also declined 8% to €2.44 billion. Stronger cloud performance offset those declines across the broader business. Consequently, cloud products remained SAP’s primary growth driver during the quarter.
Profit rises as acquisitions influence outlook SAP generated IFRS operating profit of €2.64 billion during the quarter. The result increased 8% from the previous year. Non-IFRS operating profit reached €2.74 billion, rising 7% and 9% at constant currencies.
Profit after tax increased 26% under IFRS to €2.21 billion. Basic earnings per share also climbed 30% to €1.89. Non-IFRS earnings per share increased 6% to €1.59.
Cloud gross profit reached €4.66 billion, increasing 22% year over year. The IFRS cloud gross margin declined slightly to 74.3% from 74.7%. Gross profit rose 9% to €7.23 billion despite modest margin pressure.
SAP updated its 2026 non-IFRS operating profit outlook after completing the Dremio and Prior Labs acquisitions. The company said those acquisitions created a dilutive effect on expected operating profit. It also noted sequential operating profit growth slowed because of increased research spending, stock-based compensation changes and acquisition impacts.
Cash flow strengthens as share repurchases continue SAP generated €3.15 billion in operating cash flow during the quarter. Free cash flow reached €3.00 billion, representing a 27% increase from the previous year. Those gains reflected stronger operating performance despite continued investment spending.
For the first six months of 2026, total revenue reached €19.43 billion. Cloud revenue increased 21% to €12.24 billion during the period. Operating profit also advanced 12% under both IFRS and non-IFRS reporting.
Free cash flow for the first half reached €6.25 billion. Operating cash flow increased 5% to €6.67 billion. Basic IFRS earnings per share rose 19% to €3.55 over the six-month period.
SAP also continued its previously announced share repurchase program. The company repurchased more than 16.28 million shares by June 30. Those purchases totaled about €2.6 billion at an average price of €161.16 per share under the €10 billion program announced in January 2026.
SAP has continued shifting its business toward recurring cloud revenue over recent years. That strategy has reduced reliance on traditional software licensing while expanding subscription-based enterprise software. The latest quarterly results showed that cloud demand continued supporting revenue growth, profitability, and cash generation despite acquisition costs and ongoing investments in AI and research.
Lombard Finance has launched its Bitcoin Onchain Credit Strategy with Flow Traders as an early institutional participant.
Summary
Flow Traders can borrow stablecoins while Bitcoin Earn deposits provide collateral coverage through Cap’s platform. Bitcoin holders receive underwriting premiums alongside vault returns, linking yield directly to institutional borrowing demand. Chainlink CCIP moves BTC.b from Avalanche into Ethereum, widening cross-chain access to the credit strategy. The product lets the market maker borrow stablecoins without posting its own collateral directly onchain. Instead, Bitcoin supplied through Lombard’s Bitcoin Earn vault provides separate collateral coverage through Cap’s credit platform.
The model connects Flow Traders’ demand for stablecoin financing with Bitcoin holders seeking yield. Borrowing premiums paid by the trading firm flow to depositors whose assets support the credit. Lombard said the new allocation sits inside Bitcoin Earn, which has recorded more than $1 billion in deposits from over 38,500 users.
Flow Traders borrows through Bitcoin depositors Flow Traders accesses stablecoins through Cap’s automated credit marketplace on Ethereum. Bitcoin Earn depositors supply the assets that cover the loan, while Symbiotic provides the shared-security layer. Cap’s documents say approved operators can borrow reserve assets after receiving enough collateral from delegators. Each operator receives isolated coverage rather than sharing the same collateral across several borrowers.
If a covered loan falls below its required safety level, Cap can liquidate or slash the delegated assets to repay debt. Lombard CEO Jacob Phillips said, “By separating the borrower from the collateral provider, the parties involved have made it possible for regulated, institutional trading firms to tap into onchain credit for the first time.”
Flow Traders executive Michael Lie said the strategy links Bitcoin holders with financing demand that is “less correlated to DeFi market conditions.”Flow Traders has traded digital assets since 2017 and provides liquidity across exchange-based and bilateral institutional markets.
Bitcoin Earn adds institutional credit premiums Bitcoin Earn operates as a managed meta-vault. Users can deposit LBTC, BTC.b, WBTC or native Bitcoin and receive BTCe receipt tokens. Professional managers allocate the pooled assets across several strategies rather than one lending market. Sentora manages the initial vault, while Veda supplies its infrastructure.
Lombard launched Bitcoin Earn in February 2026 as a managed Bitcoin yield product. The new credit strategy becomes one allocation within that structure. Flow Traders’ fixed annualized premium adds another source of return alongside other vault strategies, whose yields can change with market conditions.
Lombard’s documentation says BTCe withdrawals may take up to 14 days and settle in LBTC, regardless of the asset originally deposited. The company also lists smart contract, strategy and liquidity risks. Audits may reduce technical risk, but they cannot remove the chance of code failures, losses or delayed withdrawals.
Cap also states that delegators face slashing risk if an operator becomes undercollateralized. The yield therefore reflects defined credit and technical exposure rather than a guaranteed return. Cap’s risk disclosures warn that malicious or undercollateralized operators may put delegated assets at risk.
Chainlink moves BTC.b into the Ethereum vault Lombard uses Chainlink’s Cross-Chain Interoperability Protocol to move BTC.b from Avalanche into the Ethereum vault used by the strategy. CCIP lets supported applications transfer tokens and messages between blockchains. This allows the credit product to draw Bitcoin liquidity from Avalanche while Cap manages borrowing on Ethereum.
The cross-chain step follows Lombard’s May decision to use CCIP for more than $1 billion in LBTC and BTC.b assets. The company said the change aimed to standardize transfers as its Bitcoin products expanded across more networks.
As crypto.news reported, Lombard moved LBTC and BTC.b to Chainlink CCIP as its exclusive cross-chain infrastructure after reviewing its bridge setup. Lombard said the migration replaced LayerZero across several networks.
The BTC.b route follows Lombard’s acquisition of the asset and its infrastructure from Ava Labs in October 2025. As previously reported, the deal included BTC.b’s existing Avalanche integrations and user base. Lombard planned to expand the 1:1 Bitcoin asset to Ethereum, Solana and other networks.
Pilot tests a different lending structure Traditional DeFi loans usually require borrowers to post more collateral than they receive. Lombard’s structure separates the borrower from the collateral provider. Flow Traders receives stablecoins, Bitcoin Earn depositors provide coverage, and Cap’s contracts track the loan, collateral level and possible liquidation.
The setup does not remove lending risk. It depends on Lombard’s vaults, Cap’s credit contracts, Symbiotic’s collateral system, Chainlink’s cross-chain service and Flow Traders meeting its repayment duties. Problems in any connected system could affect returns, withdrawals or deposited assets.
Lombard has not disclosed the pilot loan’s size, duration, stablecoin type or interest rate. It has also not named other borrowers. The launch extends Lombard’s Bitcoin products beyond staking and standard DeFi lending, while testing whether Bitcoin depositors can support institutional stablecoin credit through an onchain structure.
According to HTX market data, Ethereum has broken through the $1900 level, with a 0.92% decline in the past 24 hours.
18 minutes ago
Analyst: If ETH holds the $1,850 support level, it may rebound to $2,060.
Crypto analyst Ali Charts posted that Ethereum rebounded after testing the lower boundary of its price channel. The current key support level stands at $1,850; as long as this level holds, Ethereum could rally back toward the channel’s upper boundary, around $2,060.
18 minutes ago
CXMT is 3 days away from its IPO, as newly opened whale positions partially cut their CXMT long positions.
According to Hyperinsight monitoring, CXMT on Hyperliquid is currently trading at $6.4658, down roughly 0.8% over 24 hours, equivalent to ~￥43.93. This is 5.07 times the ￥8.66 IPO price of Changxin Technology, representing a ~407% premium. Changxin Technology is set to list on the STAR Market on July 27 (next Monday), with stock code 688825. Its total post-IPO share count is ~668.81 billion, of which ~45.03 billion shares will be tradable from the first day of listing. Calculated at CXMT’s current price, its implied market cap is ~￥2.94 trillion, ~￥2.36 trillion higher than the IPO valuation of ￥579.188 billion. CXMT futures launched on July 15, hitting a high of $8.64 (~￥58.70) from $6 on its first day, at one point trading at a 577.8% premium to the IPO price, with its implied market cap once approaching ￥3.93 trillion. The current price has fallen 25.2% from that peak, but remains 7.8% higher than its launch price. Open interest for CXMT on the platform stands at ~$50.1 million, with 24-hour trading volume of ~$11.566 million. On the address front, the largest existing position is held by address 0xf29, which is short $8.53 million worth of CXMT at 1x leverage, with an average entry price of $6.6, unrealized profit of $170,000, and liquidation price of $15. Meanwhile, the largest recent million-dollar position (a whale address starting with 0x8e09) has started reducing its long positions; after 13:00 today, it sold a small portion of 30,000 units. As of press time, this address still holds 204,100 CXMT long positions in isolated mode at 5x leverage, with a position value of ~$1.19 million, average entry price of $6.57, unrealized loss of ~$17,000, and a return of ~-7.9%. Although this position is marked as 5x leverage, it has posted ~$1.196 million in isolated margin, resulting in an effective leverage of only ~1.1x; it is currently labeled "Hanba Xiaolong" on Hyperliquid.
18 minutes ago
Roundup of Stablecoin Demand Deposit Yields on Major CEXs: USDT Offers Up to 10% for Small-Tier Deposits, USDC Up to 8%
According to the latest compiled data on flexible savings and earn products of major centralized crypto exchanges (CEXs), platforms including HTX, Binance, OKX, and Bitget continue to offer stablecoin current yields structured as "high returns for small amounts, tiered reduction for excess amounts". For USDT: HTX’s 0-200 USDT tier has an annualized yield of 10%, dropping to 1.95% for amounts over 200 USDT; Bitget’s 0-300 USDT tier yields 6.25%, with excess amounts at 1.59%; Binance’s 0-200 USDT tier is 4.54%, excess at 1.54%; OKX’s is 1.63%. For USDC: HTX’s 0-200 USDC tier offers an annualized yield of 8%, falling to 2.75% above 200 USDC; Bitget’s 0-300 USDC tier is 6.66%, excess at 1.73%; Binance’s 0-200 USDC tier is 6.51%, excess at 1.51%; OKX’s is 1.68%. For other stablecoins: HTX’s USDT VIP tier has an annualized yield of 6%-9%, while Bitget’s USDT VIP 0-300,000 tier is 1.88%; USDE’s annualized yields on HTX, Binance, and Bitget are tiered at 5%/3%, 4.00%, and 1.81% respectively; HTX’s USDD is 4.00%; Binance’s U product has an annualized yield of 8.53% for the 0-10,000 tier, dropping to 0.53% for excess amounts. Overall, current high yields on stablecoin flexible savings products of major CEXs remain concentrated in small amounts, with yields generally lower for large sums. When comparing related products, users should not only consider the nominal annualized yield, but also note tier limits, interest calculation rules, supported currencies, and real-time product availability. The above data is displayed yield rates and does not constitute investment advice.
18 minutes ago
South Korea’s Mirae Asset Group has acquired a 97.15% stake in Korbit, and plans to develop it into a smart investment platform.
South Korea’s Mirae Asset Group has completed the acquisition of a 97.15% stake in Korbit, a veteran South Korean cryptocurrency exchange, and plans to rebrand the platform as Digital X. The deal was finalized after securing approval from South Korea’s Fair Trade Commission, and the group currently has no plans to acquire the remaining shares. Mirae Asset stated that Digital X will be positioned as a "smart investment platform" that integrates real-world assets (RWA), security token offerings (STOs), stablecoins, traditional assets, and digital assets into a unified investment ecosystem, while connecting knowledge, information, and in-depth investment research. The "X" in the name represents the unknown future and infinite possibilities arising from the convergence of different value forms. Korbit currently holds less than 1% of South Korea’s domestic crypto market share, far trailing Upbit and Bithumb. Mirae Asset emphasized that its goal is not to outperform other exchanges, but to combine its global investment expertise with Korbit’s digital asset capabilities to drive the steady, sustainable development of the digital asset industry in South Korea and globally. The group also plans to strengthen investor education, research capabilities, and institutional-grade infrastructure, while strictly adhering to anti-money laundering (AML), know-your-customer (KYC), and fraud detection standards across all operations to serve both institutional clients and retail traders.
18 minutes ago
Controversy over Morgan Stanley’s bearish stance on South Korea’s semiconductor sector intensifies, weighing on its investment banking business in the country.
South Korea’s stock market posted sharp declines today, with SK Hynix plunging over 8% and Samsung Electronics falling more than 7%. Some analysts attribute the sell-off to a recent bearish report on memory chips released by Shawn Kim, head of Asia Tech Research at Morgan Stanley, though others argue the report may not be the direct cause of the market drop. In his July 21 report, Kim noted that the AI-driven memory chip boom is nearing an inflection point, with memory contract prices likely to peak in the fourth quarter, and the share of upward earnings revisions has dropped from 92% to 77%. The report also pointed out that NAND module manufacturers’ inventories have risen to around 13 weeks, approaching the peak of roughly 15 weeks recorded during the pandemic, and put forward the trading logic: "Sell DRAM when NAND turns down." Separately, Morgan Stanley was excluded from the joint lead underwriter lineup for SK Hynix’s roughly $265 billion American Depositary Receipt (ADR) listing. The selected underwriters are Bank of America, Citigroup, Goldman Sachs, and JPMorgan Chase, leaving Morgan Stanley as the only top-tier investment bank left out. At a 0.5% underwriting fee rate, the total commission for the project is approximately $130 million. Multiple banking sources said Morgan Stanley’s Seoul office has launched internal reflection on whether its consistent negative semiconductor reports have harmed its investment banking business. Beyond the SK Hynix deal, Morgan Stanley has recently been embroiled in disputes over SpaceX’s share placement and the sale of IGIS Asset Management in South Korea. These incidents further highlight the tension between the research department’s independence and the commercial interests of investment banking, and have amplified its reputation and business pressure in the South Korean market.
Not financial or tax advice. PANews content is strictly educational and informational and is not investment advice, financial advice, tax advice, legal advice, or a solicitation to buy or sell any digital asset, security, or financial product. Do your own research and consult qualified advisers.
Disclosure. PANews may publish sponsored content, partner content, advertisements, affiliate links, event promotions, and market commentary involving Web3 projects, service providers, or financial products. PANews personnel, contributors, or affiliates may hold digital assets or other interests related to covered topics. See our Terms of Service.
Bitget has completed dividend distributions for 63 stocks including Micron Technology and TSMC.
According to an official announcement, Bitget has completed the dividend distribution for 63 US stocks and ETFs, including rMU (Micron Technology), rQQQ (Nasdaq 100 Index ETF), and rTSM (Taiwan Semiconductor Manufacturing Company, TSMC). The platform has settled USDT dividends proportionally for users who held the relevant assets at the snapshot time, with the entire process automated—no user action is required. This distribution covers multiple asset categories including technology, semiconductors, communications, and index ETFs. Users can check specific details via: in the App, navigate to "Assets" → "Financial Records" → "Spot" → "Other" → "Dividends"; or on the Web, go to "Asset Overview" → "Spot Orders" → "Fund Flow" → "Other" → "Dividends". The final credited amount and timing shall be subject to the platform’s actual credit and page display.
2 minutes ago
Ethereum breaks through $1,900
According to HTX market data, Ethereum has broken through the $1900 level, with a 0.92% decline in the past 24 hours.
2 minutes ago
Analyst: If ETH holds the $1,850 support level, it may rebound to $2,060.
Crypto analyst Ali Charts posted that Ethereum rebounded after testing the lower boundary of its price channel. The current key support level stands at $1,850; as long as this level holds, Ethereum could rally back toward the channel’s upper boundary, around $2,060.
2 minutes ago
CXMT is 3 days away from its IPO, as newly opened whale positions partially cut their CXMT long positions.
According to Hyperinsight monitoring, CXMT on Hyperliquid is currently trading at $6.4658, down roughly 0.8% over 24 hours, equivalent to ~￥43.93. This is 5.07 times the ￥8.66 IPO price of Changxin Technology, representing a ~407% premium. Changxin Technology is set to list on the STAR Market on July 27 (next Monday), with stock code 688825. Its total post-IPO share count is ~668.81 billion, of which ~45.03 billion shares will be tradable from the first day of listing. Calculated at CXMT’s current price, its implied market cap is ~￥2.94 trillion, ~￥2.36 trillion higher than the IPO valuation of ￥579.188 billion. CXMT futures launched on July 15, hitting a high of $8.64 (~￥58.70) from $6 on its first day, at one point trading at a 577.8% premium to the IPO price, with its implied market cap once approaching ￥3.93 trillion. The current price has fallen 25.2% from that peak, but remains 7.8% higher than its launch price. Open interest for CXMT on the platform stands at ~$50.1 million, with 24-hour trading volume of ~$11.566 million. On the address front, the largest existing position is held by address 0xf29, which is short $8.53 million worth of CXMT at 1x leverage, with an average entry price of $6.6, unrealized profit of $170,000, and liquidation price of $15. Meanwhile, the largest recent million-dollar position (a whale address starting with 0x8e09) has started reducing its long positions; after 13:00 today, it sold a small portion of 30,000 units. As of press time, this address still holds 204,100 CXMT long positions in isolated mode at 5x leverage, with a position value of ~$1.19 million, average entry price of $6.57, unrealized loss of ~$17,000, and a return of ~-7.9%. Although this position is marked as 5x leverage, it has posted ~$1.196 million in isolated margin, resulting in an effective leverage of only ~1.1x; it is currently labeled "Hanba Xiaolong" on Hyperliquid.
2 minutes ago
Roundup of Stablecoin Demand Deposit Yields on Major CEXs: USDT Offers Up to 10% for Small-Tier Deposits, USDC Up to 8%
According to the latest compiled data on flexible savings and earn products of major centralized crypto exchanges (CEXs), platforms including HTX, Binance, OKX, and Bitget continue to offer stablecoin current yields structured as "high returns for small amounts, tiered reduction for excess amounts". For USDT: HTX’s 0-200 USDT tier has an annualized yield of 10%, dropping to 1.95% for amounts over 200 USDT; Bitget’s 0-300 USDT tier yields 6.25%, with excess amounts at 1.59%; Binance’s 0-200 USDT tier is 4.54%, excess at 1.54%; OKX’s is 1.63%. For USDC: HTX’s 0-200 USDC tier offers an annualized yield of 8%, falling to 2.75% above 200 USDC; Bitget’s 0-300 USDC tier is 6.66%, excess at 1.73%; Binance’s 0-200 USDC tier is 6.51%, excess at 1.51%; OKX’s is 1.68%. For other stablecoins: HTX’s USDT VIP tier has an annualized yield of 6%-9%, while Bitget’s USDT VIP 0-300,000 tier is 1.88%; USDE’s annualized yields on HTX, Binance, and Bitget are tiered at 5%/3%, 4.00%, and 1.81% respectively; HTX’s USDD is 4.00%; Binance’s U product has an annualized yield of 8.53% for the 0-10,000 tier, dropping to 0.53% for excess amounts. Overall, current high yields on stablecoin flexible savings products of major CEXs remain concentrated in small amounts, with yields generally lower for large sums. When comparing related products, users should not only consider the nominal annualized yield, but also note tier limits, interest calculation rules, supported currencies, and real-time product availability. The above data is displayed yield rates and does not constitute investment advice.
2 minutes ago
South Korea’s Mirae Asset Group has acquired a 97.15% stake in Korbit, and plans to develop it into a smart investment platform.
South Korea’s Mirae Asset Group has completed the acquisition of a 97.15% stake in Korbit, a veteran South Korean cryptocurrency exchange, and plans to rebrand the platform as Digital X. The deal was finalized after securing approval from South Korea’s Fair Trade Commission, and the group currently has no plans to acquire the remaining shares. Mirae Asset stated that Digital X will be positioned as a "smart investment platform" that integrates real-world assets (RWA), security token offerings (STOs), stablecoins, traditional assets, and digital assets into a unified investment ecosystem, while connecting knowledge, information, and in-depth investment research. The "X" in the name represents the unknown future and infinite possibilities arising from the convergence of different value forms. Korbit currently holds less than 1% of South Korea’s domestic crypto market share, far trailing Upbit and Bithumb. Mirae Asset emphasized that its goal is not to outperform other exchanges, but to combine its global investment expertise with Korbit’s digital asset capabilities to drive the steady, sustainable development of the digital asset industry in South Korea and globally. The group also plans to strengthen investor education, research capabilities, and institutional-grade infrastructure, while strictly adhering to anti-money laundering (AML), know-your-customer (KYC), and fraud detection standards across all operations to serve both institutional clients and retail traders.
Oasis Pro Markets Secures Regulatory Green LightOndo Finance has cleared a significant regulatory hurdle in its push to bring tokenized securities to American investors. Its SEC-registered broker-dealer subsidiary, Oasis Pro Markets, has received U.S. regulatory authorization to offer compliant tokenized corporate equities and funds to U.S. financial institutions and retail investors under SEC and FINRA oversight, via OTC retailing, underwritten primary offerings, private placements, and other activities.
Oasis Pro Markets LLC operates as an SEC-registered broker-dealer and alternative trading system and is a member of FINRA/SIPC. The authorizations further enable Oasis Pro Markets to operate a compliant platform for U.S. issuers to conduct primary offerings of, and for U.S. institutional and retail investors to engage in secondary trading of, these tokenized securities.
U.S. investors will gain access to publicly traded equities, including IPOs, as well as fund interests such as ETFs, mutual funds, and index funds. Ondo says the approval will help deliver 24-hour trading, fractional ownership, and faster settlement to investors across the country.
Broader Access and Growing MomentumThe approvals further allow Oasis Pro Markets to support omnibus account structures through integrations with existing broker-dealer and advisory channels, enabling institutional investors, registered investment advisers, and retirement accounts to access tokenized securities through their current brokers, significantly reducing onboarding friction and enabling broader participation by U.S. investors.
The announcement builds on momentum Ondo has already established in the tokenized securities space. Ondo Finance said it has recorded $20 billion in cumulative trading volume and $1 billion in total value locked (TVL) for tokenized stocks, and that it will continue expanding infrastructure connecting traditional finance and blockchain.
Earlier this month, Ondo Finance expanded its tokenized securities offering on Solana by introducing 24/7 minting and redemption for select U.S. stocks and ETFs, with the rollout initially covering six assets: NVDAon, TSLAon, GOOGLon, SPYon, QQQon, and CRCLon. Ondo also introduced tokenized versions of BlackRock's iShares Core S&P 500 ETF and Micron shares in partnership with Broadridge, with the underlying securities remaining within the established U.S. custody system while corresponding tokens are issued on Ethereum and held by regulated custodians.
The move comes as tokenized equities gain momentum across both crypto and traditional finance, with Robinhood rolling out its own blockchain and expanding tokenized stocks beyond Europe, while the DTCC has expanded blockchain-based infrastructure and exchanges including Nasdaq and the NYSE have announced tokenization initiatives.
Sources:
Ondo Finance Official Press Release via PR Newswire
Crypto Times: Ondo's Oasis Pro Gets SEC, FINRA Nod for Tokenized Stocks
CoinDesk: Ondo Finance Debuts SEC-Aligned Tokenized Stock Model
The Pound to Australian Dollar (GBP/AUD) exchange rate fell to a near one-month low on Thursday after stronger-than-expected Australian employment figures boosted the ‘Aussie’.
At the time of writing, GBP/AUD was trading around AU$1.9091, having recovered from an intraday low of approximately AU$1.9066.
Latest — Exchange Rates:
Pound to Australian Dollar (GBP/AUD): 1.911595 (-0.12%)
Pound to Dollar (GBP/USD): 1.332 (-0.41%)
DAILY RECAP:
The Australian Dollar (AUD) strengthened during Thursday’s Asian trading session following the release of Australia’s latest employment report.
The data showed employment increased by 76,300 in June, comfortably beating forecasts for a rise of 15,000.
The stronger-than-expected labour market reinforced expectations that the Reserve Bank of Australia (RBA) could continue raising interest rates later this year.
However, the risk-sensitive ‘Aussie’ struggled to hold onto all of its gains as a cautious market mood weighed on demand during European trade.
Meanwhile, the Pound (GBP) remained subdued as markets continued to assess Andy Burnham’s first week as Prime Minister.
Sterling had strengthened in the run-up to Burnham entering Downing Street as investors unwound the political risk premium previously built into the currency.
However, the Pound has since trended lower amid ongoing questions over how the government's spending commitments and tax cut pledges will be financed.
This uncertainty continued to limit Sterling on Thursday.
Near-Term GBP/AUD Forecast: PMI Surveys in Focus Looking ahead, Friday's Asian session brings Australia's preliminary PMI surveys.
If private sector activity slowed to near-stagnation in July, as expected, the Australian Dollar could face renewed pressure.
European trading then begins with the UK's June retail sales figures. A forecast 0.3% contraction in sales could weigh on Sterling.
Later in the morning, attention turns to the UK's preliminary PMI surveys, with investors particularly focused on the services reading. Any improvement in business activity could provide the Pound with modest support.
Meanwhile, broader market risk appetite and UK political developments are also likely to influence GBP/AUD trading, potentially leading to increased volatility.
The Pound to US Dollar (GBP/USD) exchange rate traded in a narrow range on Thursday as investors continued to assess Prime Minister Andy Burnham's first week in office while awaiting fresh economic data.
At the time of writing, GBP/USD was trading around $1.3362, down marginally on the day.
Latest — Exchange Rates:
Pound to Dollar (GBP/USD): 1.3319 (-0.42%)
Euro to Dollar (EUR/USD): 1.137743 (-0.30%)
Dollar to Yen (USD/JPY): 163.85814 (+0.47%)
DAILY RECAP:
The Pound (GBP) traded with modest losses on Thursday as markets continued to assess Andy Burnham’s first week as Prime Minister.
Sterling had rallied ahead of Burnham’s arrival in Downing Street as investors unwound the political risk premium previously priced into the currency.
However, the Pound edged lower this week amid lingering concerns over how the government's new spending commitments and tax cuts will be financed.
Losses in Sterling were somewhat limited by hopes that the proposed measures could support economic growth.
Plans including a 20% cut in business rates for pubs, clubs and music venues in England, alongside lower VAT on household energy bills, helped temper some fiscal concerns, although GBP investors remained cautious.
Meanwhile, the US Dollar (USD) lacked clear direction as a quiet US economic calendar and mixed market sentiment left the safe-haven currency rangebound.
While global markets remain concerned about the escalating conflict in the Middle East, broader risk appetite has proved surprisingly resilient despite the worsening geopolitical backdrop.
Some investors continued to hope that diplomatic efforts could eventually produce a peace agreement, although optimism appeared to be fading.
Near-Term GBP/USD Forecast: PMI Surveys in the Spotlight Looking ahead, the UK's June retail sales figures will be the first major release on Friday.
Economists expect sales to have fallen by 0.3%, which could place the Pound under pressure.
Attention will then turn to the UK's latest PMI surveys, with the services index expected to be the key focus for Sterling investors. Any improvement in business activity during July could help support the Pound.
Meanwhile, the US S&P Global PMI surveys will be released later in the day. While typically less influential than the ISM reports, stronger-than-expected readings could still provide the US Dollar with additional support.
Booz Allen Hamilton (NYSE:BAH) held its 2026 annual meeting of stockholders on July 22, with shareholders approving the company’s three management proposals and rejecting a shareholder proposal seeking to expand the right to act by written consent.
The virtual meeting was led by Jacob Bernstein, Booz Allen’s Deputy General Counsel and Secretary, and Horacio Rozanski, the company’s Chairman and Chief Executive Officer. Bernstein said a quorum was present and that notice of the meeting and proxy materials had been mailed beginning June 11 to stockholders of record as of June 1.
Shareholders Approve Management Proposals Rozanski said the board recommended that stockholders vote in favor of management proposals one, two and three, and against proposal four, which had been submitted by a stockholder. The transcript did not detail the substance of the first three proposals beyond noting that they were outlined in the company’s proxy statement.
After voting closed, Bernstein said the Inspector of Election had completed a preliminary tabulation. He reported that proposals one, two and three had been “duly approved” by stockholders, while proposal four had not been approved. Bernstein said the final vote tabulation would be filed with the Securities and Exchange Commission within four business days.
Written Consent Proposal Rejected Proposal four was presented by John Chevedden, a private investor and shareholder proponent. Chevedden asked shareholders to support a proposal requesting that Booz Allen’s board take steps to permit shareholders to act by written consent with the minimum number of votes required to authorize an action at a meeting where all shareholders entitled to vote were present and voting.
Chevedden argued that the right to act by written consent would allow shareholders to put forward proposals on a timely basis without waiting for the next annual meeting. He said written consent is designed for issues with broad shareholder support and requires formal backing from a majority of all shares outstanding.
“Many companies incorrectly give the impression that written consent gives too much influence to a minority,” Chevedden said, adding that, in his view, a minority’s role would be limited to initiating a proposal capable of attracting broad support.
CEO Cites Technology Shifts and Market Uncertainty Following the formal portion of the meeting, Rozanski offered remarks on Booz Allen’s market positioning and operating environment. He said “American technology leadership has never been more important” and described Booz Allen’s work as focused on national security, homeland defense and essential civilian services.
Rozanski pointed to several technology and market trends, including the development of “agentic” artificial intelligence, increasingly autonomous cyber threats and the convergence of powerful technologies. He also said the government is placing greater emphasis on speed, commercial technology, outcome-based acquisition and accountability.
“Booz Allen has been advocating, preparing, and investing for these types of changes for years,” Rozanski said. He added that the company believes those shifts will be positive for the country, its customers, Booz Allen and its stockholders over time, while acknowledging that large-scale changes can create near-term uncertainty and disruption.
Fiscal 2026 Described as Challenging Rozanski said fiscal 2026, which ended March 31, reflected that uncertainty. He described the year as challenging, with results shaped by “significant market changes and a highly dynamic macro environment.”
He said the company focused on execution, investment and strategic transformation during the period. “As a result, Booz Allen is stronger than we were a year ago,” Rozanski said. “We are more focused, more agile, and better positioned to lead in a market defined by speed, accountability, and technology-driven outcomes.”
Rozanski said Booz Allen believes its investments in artificial intelligence, cyber, defense technology and next-generation technologies will drive “substantial shareholder value in the medium term.”
No stockholder questions were submitted during the meeting’s question-and-answer period, Bernstein said. Ernst & Young representatives Jill Wheeler and Caitlin Bell were present and available to respond to questions concerning the company’s financial statements, according to Rozanski.
About Booz Allen Hamilton (NYSE:BAH) Booz Allen Hamilton Holding Corporation is a publicly traded management and technology consulting firm headquartered in McLean, Virginia. The company provides a wide range of professional services and solutions in strategy, analytics, digital transformation, engineering and cyber security. Its expertise spans from supporting federal civilian agencies to defense, intelligence and homeland security organizations, as well as select commercial industries.
Key offerings include data analytics and artificial intelligence applications, software development and modernization, systems integration, and cyber risk management.
« PREVIOUS HEADLINEBest Chinese Stocks To Research – July 22nd
NEXT HEADLINE »Hochschild Mining Stays on Track After Solid Q2, but Costs Run Above Guidance
Index spotřebitelské důvěry (červenec):
aktuální hodnota: 105,6 b.
očekávání trhu: 107,0 b.
předchozí hodnota: 106,5
Spotřebitelská a podnikatelská důvěra (červenec):
aktuální hodnota: 101,1 b.
očekávání trhu: 101,5 b.
předchozí hodnota: 101,0 b.
Podnikatelská důvěra (červenec):
aktuální hodnota: 100,2 b.
očekávání trhu: 99,8 b.
předchozí hodnota: 99,8 b.
„Důvěra podnikatelů v ekonomiku se v červenci zvýšila ve všech sledovaných odvětvích, což vedlo k jejímu návratu na úroveň dlouhodobého průměru. Z průzkumů je ale patrné, že mezi respondenty přetrvává vysoká míra nejistoty související především s geopolitickým vývojem ve světě,“ uvedl Jiří Obst, vedoucí oddělení konjunkturálních průzkumů ČSÚ.
„Červencové zhoršení spotřebitelské důvěry odráží rostoucí nejistotu domácností ohledně jejich finanční situace i hospodářského vývoje v České republice v následujících 12 měsících,“ sdělila Veronika Ptáčková z oddělení konjunkturálních průzkumů ČSÚ.
Přední asijsko-pacifické indexy uzavřely páteční obchodování v červených číslech. Investoři pokračovali ve výprodejích v návaznosti na obavy růstu kapitálových výdajů na umělou inteligenci. Indexy reagovali výsledky společnosti Alphabet, která navýšila výhled kapitálových výdajů v tomto roce a v roce následujícím by tyto výdaje měly nadále růst. Největší pokles zaznamenal jihokorejský index Kospi (-5,7 %).
Japonský Nikkei 225 -2,73 % na 64611,15 b.
Hongkongský Hang Seng -1,39 % na 24859,73 b.
Čínský Shanghai Composite -1,61 % na 3814,1978 b.
Jihokorejský Kospi -5,72 % na 6690,62 b.
Australský S&P/ASX 200 -0,75 % na 8772,3 b.
Not financial or tax advice. PANews content is strictly educational and informational and is not investment advice, financial advice, tax advice, legal advice, or a solicitation to buy or sell any digital asset, security, or financial product. Do your own research and consult qualified advisers.
Disclosure. PANews may publish sponsored content, partner content, advertisements, affiliate links, event promotions, and market commentary involving Web3 projects, service providers, or financial products. PANews personnel, contributors, or affiliates may hold digital assets or other interests related to covered topics. See our Terms of Service.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
The USD/CAD pair trades in negative territory near 1.4075 during the early European trading hours on Friday. Escalating conflicts in the Middle East boost crude oil prices, supporting the commodity-linked Canadian Dollar (CAD) against the US Dollar (USD).
Oil prices spiked after Yemen’s Iran-backed Houthi rebels attacked oil tankers in the Red Sea, threatening a key export route that Saudi Arabia has used to bypass the Strait of Hormuz. US President Donald Trump said that the US would hold Iran responsible for the Houthis’ actions and warned that Iran and its Houthi allies would both soon receive a “major military punishment.”
It is worth noting that Canada is a major oil-exporting country, and high crude oil prices generally have a positive impact on the Loonie.
The preliminary readings of the US S&P Global Purchasing Managers Index (PMI) will be in the spotlight later on Friday. If the report shows stronger-than-expected outcomes, this could help limit the Greenback’s losses in the near term.
Technical Analysis:In the daily chart, USD/CAD keeps the bullish vibe, with the price holding above the 100-day Simple Moving Average (SMA). However, the pair slips back under the 20-day Bollinger SMA, signaling a loss of immediate topside traction after the recent spike. The 14-day Relative Strength Index at 47.9 sits just below the midline, hinting at directionless momentum in the near term as neither bulls nor bears currently dominate.
On the topside, initial resistance is aligned with the 20-day Bollinger SMA around 1.4130, ahead of a stronger barrier at the upper Bollinger Band near 1.4262. On the downside, the lower Bollinger Band at approximately 1.4000 offers the first line of support, with the 100-day SMA at 1.3875 reinforcing a deeper demand zone if selling pressure extends.
(The technical analysis of this story was written with the help of an AI tool. Know more.)
Us trade comments ease concern over Canada tariffsStrategists at Scotiabank highlight a more constructive tone from US officials on the latest tariff measures, noting that US Trade Representative Greer “offered some hope that the latest tariff blast from Washington would not undermine US/Canada trade relations in the long run and that talks could make progress towards a broader agreement before year-end.” This, they suggest, helps temper market anxiety around the bilateral trade outlook even as currency markets continue to track the broader US Dollar trend.
Canadian Dollar FAQs The key factors driving the Canadian Dollar (CAD) are the level of interest rates set by the Bank of Canada (BoC), the price of Oil, Canada’s largest export, the health of its economy, inflation and the Trade Balance, which is the difference between the value of Canada’s exports versus its imports. Other factors include market sentiment – whether investors are taking on more risky assets (risk-on) or seeking safe-havens (risk-off) – with risk-on being CAD-positive. As its largest trading partner, the health of the US economy is also a key factor influencing the Canadian Dollar.
The Bank of Canada (BoC) has a significant influence on the Canadian Dollar by setting the level of interest rates that banks can lend to one another. This influences the level of interest rates for everyone. The main goal of the BoC is to maintain inflation at 1-3% by adjusting interest rates up or down. Relatively higher interest rates tend to be positive for the CAD. The Bank of Canada can also use quantitative easing and tightening to influence credit conditions, with the former CAD-negative and the latter CAD-positive.
The price of Oil is a key factor impacting the value of the Canadian Dollar. Petroleum is Canada’s biggest export, so Oil price tends to have an immediate impact on the CAD value. Generally, if Oil price rises CAD also goes up, as aggregate demand for the currency increases. The opposite is the case if the price of Oil falls. Higher Oil prices also tend to result in a greater likelihood of a positive Trade Balance, which is also supportive of the CAD.
While inflation had always traditionally been thought of as a negative factor for a currency since it lowers the value of money, the opposite has actually been the case in modern times with the relaxation of cross-border capital controls. Higher inflation tends to lead central banks to put up interest rates which attracts more capital inflows from global investors seeking a lucrative place to keep their money. This increases demand for the local currency, which in Canada’s case is the Canadian Dollar.
Macroeconomic data releases gauge the health of the economy and can have an impact on the Canadian Dollar. Indicators such as GDP, Manufacturing and Services PMIs, employment, and consumer sentiment surveys can all influence the direction of the CAD. A strong economy is good for the Canadian Dollar. Not only does it attract more foreign investment but it may encourage the Bank of Canada to put up interest rates, leading to a stronger currency. If economic data is weak, however, the CAD is likely to fall.
HAYWARD, Calif. & MIAMI--(BUSINESS WIRE)---- $SMMT--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, and Summit Therapeutics Inc. (Nasdaq: SMMT), a biopharmaceutical company focused on patient-friendly oncology therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical ne.
Equinor ASA (NYSE:EQNR) reported higher second-quarter earnings and production, with Chief Financial Officer Torgrim Reitan saying the company is executing in line with plans presented at its recent Capital Markets Day to grow energy output, cash flow and returns through 2030.
Reitan said Equinor produced 2.165 million barrels of oil equivalent per day in the quarter, up 3% from the same period last year. Adjusted operating income totaled $11.5 billion before tax, while IFRS net income was $4.8 billion. Adjusted earnings per share were $1.33. Cash flow from operations after tax reached $13.7 billion year to date.
“While energy markets remain impacted by geopolitical unrest, we continue to focus on what we control, our operations, how we remain robust through price cycles, and our commitment to cost and capital discipline,” Reitan said.
Production Growth Driven by Norway and New Fields Reitan said production on the Norwegian continental shelf rose 4%, driven by new fields including Johan Castberg, Halten East and Verdande, with Eirin and Symra also coming on stream during the quarter. He highlighted another strong quarter from Johan Sverdrup, where Equinor now expects the annual decline to be at the low end of its previously indicated 10% to 20% range.
Production was affected by turnarounds, maintenance and a temporary outage at Johan Castberg. In response to an analyst question, Reitan said issues related to turbine waste heat took 18 days to resolve, and the field resumed production on July 13. He said the impact to Equinor in the third quarter would be about 14,000 barrels per day.
Internationally, production growth was supported by Adura in the U.K. and Bacalhau in Brazil, offsetting lower ownership in Peregrino and the divestment of onshore Argentina assets. Reitan said first-half production growth totaled 6%, making the company’s full-year guidance of 3% growth “more robust,” though Equinor left its production guidance unchanged.
Financial Results Lifted by Prices, Trading and Refining Equinor said liquids and European gas prices were higher than the same quarter last year, while U.S. gas prices were lower. Adjusted operating income in E&P Norway was $9.2 billion before tax and $2.1 billion after tax. In international E&P, Reitan said operating income nearly doubled on 4% production growth and an improved portfolio.
The company’s Marketing, Midstream and Processing segment delivered $777 million in pretax income, well above its $400 million-per-quarter guidance. Reitan attributed the performance to crude trading and strong results at the Mongstad refinery, which benefited from higher margins. He said European refinery product markets were tight, with FCC margins around $25 per barrel in the second quarter, and that Mongstad continued to deliver strong results early in the third quarter.
Power results reflected a strong contribution from power trading for a second consecutive quarter. Equinor produced 1.2 terawatt-hours of power in the quarter, with growth from Dogger Bank in the U.K. and new onshore assets.
Cash Flow, Divestments and Shareholder Returns Cash flow from operations before tax was $14.8 billion in the quarter. Equinor paid $7.1 billion in taxes, including three Norwegian continental shelf installments totaling about $6.4 billion. Organic capital expenditure was $3.4 billion, and net cash flow before distributions was positive $5.5 billion.
The company distributed $1.1 billion to shareholders during the quarter. Its board approved an ordinary cash dividend of $0.39 per share and a third tranche of share buybacks of up to $1.125 billion, including the Norwegian state’s share.
Reitan said Equinor ended the quarter with about $24 billion in cash and cash equivalents, while its net debt ratio declined to 10.4%. At current forward prices, he said the company expects the net debt ratio to be somewhat below 10% at year-end.
Equinor also recorded proceeds from portfolio actions. The sale of Argentina onshore assets generated $558 million in proceeds during the quarter, in addition to $88 million received in the first quarter, and Equinor recorded a $467 million gain. A partial divestment of its financial position in Scatec generated $171 million in proceeds and an accumulated recorded gain of $61 million.
Gas Market Outlook and Capital Allocation Asked about European natural gas markets, Reitan described the situation as “vulnerable” heading into autumn and winter, citing uncertainty around LNG flows and European storage levels. He said storage was 53% full, more than 15 percentage points below average, and that Equinor does not expect Europe to reach 80% storage before winter.
Reitan said Equinor is already producing gas at maximum levels in the short term, but can optimize flows through its production and transportation system toward markets where gas is most needed and prices are highest. He said Equinor keeps its natural gas exposure floating, with 70% linked to day-ahead prices and 30% to month-ahead prices.
On whether strong cash flow could lead to share buybacks above the $3 billion now planned for the year, Reitan said no. He said additional cash has been directed toward increasing oil and gas investments by $1 billion, strengthening the balance sheet and doubling the share buyback program for the year.
Project Pipeline and Cost Focus Reitan pointed to several projects supporting future growth, including the ramp-up of Bacalhau, which he said is expected to reach plateau by year-end. He also cited Raia in Brazil, Sparta in the Gulf of Mexico, Rosebank and Jekta in the U.K., and the recently sanctioned Greater PAJ project in Angola.
On Bay du Nord in Canada, Reitan said BP is handing its ownership to Equinor and that the timeline remains unchanged, with a sanctioning target in 2027. He said Equinor is working to bring in another partner and described the project as supported by the Canadian government.
Reitan said Equinor continues to manage cost inflation through portfolio-level contracting, standardization and simplification. He said the company’s new developments have a break-even below $40 per barrel and that its NCS 2035 operating model aims to double development speed and cut costs by half across a portfolio of projects.
Equinor left its guidance unchanged for production, capital spending and capital distribution, with Reitan saying the quarter demonstrated progress toward the company’s stated objectives of increasing production by 150,000 barrels per day to 2030, growing cash flow from operations by 30% and targeting a 15% return on capital employed through the decade.
About Equinor ASA (NYSE:EQNR) Equinor ASA (NYSE: EQNR) is a Norway-based integrated energy company headquartered in Stavanger. Historically established as Statoil in the 1970s to develop Norway’s petroleum resources, the company changed its name to Equinor in 2018 to reflect a strategic shift toward a broader energy portfolio. Equinor’s operations span the full upstream value chain, including exploration, development and production of oil and natural gas, alongside trading and marketing activities that support its global commercial operations.
In recent years Equinor has pursued a transition strategy that combines continued development of conventional oil and gas resources with growing investments in low‑carbon energy.
SL Green Realty Corp. (SLG) Q2 2026 Earnings Call July 23, 2026 2:00 PM EDT
Company Participants
Marc Holliday - Chairman & CEO
Matthew Diliberto - Chief Financial Officer
Steven Durels - Executive VP and Director of Leasing & Real Property
Harrison Sitomer - President & Chief Investment Officer
Robert DeWitt
Conference Call Participants
Nicholas Yulico - Scotiabank Global Banking and Markets, Research Division
Alexander Goldfarb - Piper Sandler & Co., Research Division
Steve Sakwa - Evercore ISI Institutional Equities, Research Division
Thomas Catherwood
John Kim - BMO Capital Markets Equity Research
Blaine Heck - Wells Fargo Securities, LLC, Research Division
Peter Abramowitz - Deutsche Bank AG, Research Division
Anthony Paolone - JPMorgan Chase & Co, Research Division
Seth Bergey - Citigroup Inc., Research Division
Vikram Malhotra - Mizuho Securities USA LLC, Research Division
Ronald Kamdem - Morgan Stanley, Research Division
Brendan Lynch - Barclays Bank PLC, Research Division
Caitlin Burrows - Goldman Sachs Group, Inc., Research Division
Michael Lewis - Truist Securities, Inc., Research Division
Presentation
Operator
Thank you, everybody, for joining us, and welcome to SL Green Realty Corp. Second Quarter 2026 Earnings Results Conference Call. This conference call is being recorded. At this time, the company would like to remind listeners that during the call, management may make forward-looking statements. You should not rely on forward-looking statements as predictions of future events as actual results and events may differ from any forward-looking statements that management may make today.
All forward-looking statements made by management on this call are based on their assumptions and beliefs as of today. Additional information regarding the risks, uncertainties and other factors that could cause such differences to appear are set forth in the risk factors and MD&A sections of the company's latest Form 10-K and other subsequent reports filed by the company with the Securities and Exchange Commission.
Also, during today's conference call, the company may discuss non-GAAP financial
ECB včera v souladu s všeobecným očekáváním ponechala depozitní sazbu beze změny na 2,25 %. Finanční trhy však mnohem více zajímalo, zda centrální banka nabídne alespoň náznak toho, jak hodlá reagovat na nový energetický šok vyvolaný námořní blokádou Husijů v Rudém moři. Toho se však investoři nedočkali.
Prezidentka Christine Lagardeová znovu zdůraznila přístup „zasedání od zasedání“ a závislost měnové politiky na příchozích makroekonomických datech. ECB sice připustila, že aktuální ceny energií se zatím pohybují poblíž základního scénáře červnové prognózy, zároveň ale bude pečlivě vyhodnocovat, zda vyšší ceny ropy a především zemního plynu nezanechají trvalejší stopu v inflaci prostřednictvím sekundárních efektů.
Zajímavý moment nicméně zazněl během tiskové konference. Přestože bylo včerejší rozhodnutí jednomyslné, někteří členové Rady guvernérů si podle Lagardeové kladli otázku, zda by nebylo vhodné zvýšit sazby již nyní. Pro finanční trhy to byl další argument, proč nepřehodnocovat sázky na zářijové zvýšení sazeb. To je nyní téměř plně zaceněno a investoři zároveň počítají s tím, že ECB do konce roku přidá ještě jedno zvýšení o 25 bazických bodů (depozitní sazba by tak vzrostla na 2,75 %).
Prezidentka ECB navíc poznamenala, že finanční trhy velmi dobře rozumějí reakční funkci centrální banky. My si tento komentář vykládáme jako poměrně silný signál, že na zářijovém zasedání skutečně dojde ke zvýšení sazeb o 25 bazických bodů, a tomuto scénáři přizpůsobujeme i náš výhled eurových úrokových sazeb.
Vedle zasedání ECB se však odehrával ještě jeden z nejzajímavějších příběhů posledních týdnů na dluhopisových trzích. Eskalace napětí v Rudém moři – druhé klíčové dopravní tepně z Blízkého východu – tlačí vzhůru nejen ceny ropy, ale především evropské ceny zemního plynu. To se postupně promítá i do růstu dluhopisových výnosů. Německé výnosy napříč splatnostmi atakují nejvyšší úrovně za mnoho let a dvouletý eurový swap se již vyšplhal nad 3 %. Trh tak stále více sází na scénář, v němž úrokové sazby zůstanou zvýšené déle, než se ještě před několika týdny očekávalo.
Právě delší konec výnosových křivek přitom přepisuje historické milníky. Výnos desetiletého francouzského státního dluhopisu krátce překonal hranici 4 % poprvé od roku 2009, zatímco některé německé splatnosti se dostávají na úrovně naposledy zaznamenané před globální finanční krizí. Podobný obrázek nabízí i Spojené státy, kde výnos třicetiletého vládního dluhopisu opět atakuje letošní květnová maxima, která byla nejvyšší od roku 2007. Jinými slovy, dluhopisové trhy začínají stále vážněji zohledňovat možnost, že současný energetický šok nebude pouze krátkodobou epizodou, ale faktorem, který může centrálním bankám výrazně zkomplikovat návrat inflace k cíli i ve střednědobém horizontu.
TRHY
Koruna
Vyšší ceny plynu, odrážející uzavřený Hormuzský průliv a nové napětí v Rudém moři jsou rizikem i pro náš inflační výhled v Česku. Spotové ceny plynu v Amsterdamu vystoupaly na nejvyšší úrovně od začátku roku (62,5 EUR/MWH) a spolu s nimi rostou i forwardové ceny na rok 2027. Pravě proto nově vidíme inflaci v příštím roce o desetinku výše na 3,3% a rizika jsou v tuto chvíli vychýlena spíše směrem vzhůru.
Pro ČNB to zatím nic bezprostředně neznamená - inflace v nejbližších měsících zůstane velmi nízká. Pokud současný tlak na trzích vydrží, výrazně však vzroste pravděpodobnost dalšího růstu sazeb na konci roku 2026.
Korunu zatím geopolitická nejistota netrápí a drží se i nadále v blízkosti 24,20 EUR/CZK.
Eurodolar
Kombinace cen ropy nad hranicí 100 USD za barel, překvapivě silných makroekonomických dat z USA a ECB, která nevyloučila zvýšení sazeb již na zářijovém zasedání (viz úvodník), vedla k výraznému posunu tržních očekávání. Investoři začali spekulovat, že Fed by mohl přistoupit ke zvýšení sazeb již příští středu. Výsledkem byl prudký růst dolarových úrokových sazeb a výrazné posílení americké měny, a to nejen vůči euru, ale například i vůči japonskému jenu.
Náš základní scénář nicméně nadále předpokládá, že Fed sazby na nejbližším zasedání ponechá beze změny a k případnému zvýšení přistoupí až v září. Domníváme se však, že finanční trhy budou tímto příběhem žít minimálně do nadcházejícího zasedání Fedu, což bude eurodolar držet pod tlakem. Dolar navíc může zůstat silný tím spíše, pokud se ceny ropy udrží poblíž současných úrovní, případně zamíří ještě výše.
Včerejší výprodeje v Evropě (-1,5 %) a USA (SP500 -1,2 %) se v noci přenesly do Asie. Region ztratil -2,4 %, lídři jako Samsung a Hynix klesli o přibližně -7 %. Raketový růst cen energií, kdy ropa Brent vystoupala k metě 100 USD za barel, zhoršil sentiment na trhu. Investoři se navíc potýkají s pochybnostmi o výnosech z investic do AI. Aktuálně futures kontrakty na indexy naznačují v pátek ráno v Evropě snahu o konsolidaci po čtvrtečním propadu. Nevýrazné jsou také zámořské futures. Intel po závěru obchodování včera překonal odhady, ale po růstu se akcie následně vracely zpět. Pokračuje výsledková sezóna, ráno reportoval SAP (příjmy z cloudu rostly rychlejším tempem, než odhady trhu). Volkswagen snížil odhady tržeb pro tento rok, především klesají prodeje v Číně. V Praze Moneta zvýšila celoroční prognózu čistého zisku, nyní vidí 6,8 mld. CZK (předtím 6,6 mld. CZK). Akcie Moneta by mohly zareagovat pozitivně, uvidíme, zdali se jim podaří návrat nad 190 Kč. Celkově index PX včera oslabil -0,7 %, podle očekávání se nedařilo Erste (-3 %). Růst cen komodit naopak vyhovuje ČEZu (+0,7 %).
Space Exploration Technologies (SPCX +2.56%) has grand ambitions, including sending humans to Mars. This may require breakthroughs in space travel even more impressive than those the company has already achieved. It's not surprising, then, that Ark Investment Management -- a firm led by the famous investor Cathie Wood, a staunch believer in the power of innovation -- is doubling down on SpaceX stock. The space company is the fourth-largest holding across Ark Investment Management's combined portfolio, with the firm buying more shares as recently as July 22. However, I wouldn't follow in Wood's footsteps on this one. Here's why I am not ready to buy SpaceX stock yet.
Image source: Getty Images.
The price is not right First, let's give credit where credit is due. SpaceX has already revolutionized space travel and is currently a leader in providing orbital launch services to U.S. government agencies. The company is still making progress. SpaceX is developing a next-gen rocket, Starship, that could significantly reduce launch costs. SpaceX will make progress elsewhere thanks to Starship, including in its Starlink segment, where it provides internet services through a constellation of Low Earth Orbit satellites. Starship will help SpaceX launch substantially more satellites into orbit, thereby improving its services and expanding its addressable market.
SpaceX's artificial intelligence (AI) business also seems to be slowly taking off. The company has a deal in place to provide Alphabet (GOOG -6.89%) (GOOGL -7.12%) with compute capacity. SpaceX is also reportedly in talks to provide computing power to the U.S. Department of Defense in a potential multi-billion-dollar deal. Over the next few years, SpaceX could record growing revenue thanks to Starlink, which already boasts 10.3 million subscribers, a number that should keep growing at a good clip. We could also see revenue growth in its space and AI units ramping up.
Today's Change
(
2.56
%) $
2.95
Current Price
$
118.21
However, SpaceX likely won't be consistently profitable anytime soon. The company is investing heavily to tap into what it sees as transformational opportunities. That's especially true in its AI business, where it is spending more on capex than in its two other segments combined. Whether or not that's the right move, time will tell. But for a company worth $1.6 trillion, it's hard to justify a revenue of just $4.7 billion in the first quarter of 2026, which increased by just 15% year over year.
At its current valuation, SpaceX's revenue should either be much higher or should be growing much faster (or both). Note that the company's price-to-sales ratio is an incredible 78.09 as of this writing. That's far too high by any standard, particularly since the reasonably valued range typically starts below "2." All of this suggests the market is already factoring in SpaceX's success across its connectivity and, especially, its AI businesses, and the stock could decline over the next few years as it faces increased competition. That's why the company's shares aren't attractive right now. They'd have to drop significantly from current levels before becoming so.
Japan’s Nikkei fell sharply on Friday as Alphabet’s spending plans revived doubts over how quickly the artificial-intelligence boom will translate into cash returns for the companies funding it.
The Nikkei 225 dropped 2.69% to 64,634.04 in early trading, while the broader Topix lost 1.28% to 4,002.09.
The gap reflected concentrated selling in the technology heavyweights that dominate the Nikkei.
The benchmark has now fallen more than 7% in July after entering correction territory last week, leaving investors increasingly sensitive to signals from US chip and platform companies.
Alphabet shares sank about 7% in New York even after Google Cloud revenue surged 82% to $24.8 billion.
Investors instead focused on second-quarter capital expenditure of $44.9 billion and negative free cash flow of $5.9 billion, both driven by the rapid expansion of AI infrastructure.
The Google parent also raised its 2026 capital-spending forecast to between $195 billion and $205 billion from $180 billion to $190 billion.
Management said spending would remain elevated as customer demand continued to exceed available computing capacity.
The market reaction showed that growth alone is no longer enough.
Investors increasingly want evidence that higher data-centre and server spending can produce durable cash returns, rather than only faster revenue and cloud bookings.
That concern also dragged the Nasdaq more than 2% lower overnight.
The sell-off hit the companies most closely tied to the AI hardware cycle.
Advantest dropped 6.33%, Tokyo Electron lost 5.43% and memory producer Kioxia declined 4.4%. SoftBank Group slid 7.42%, making it one of the largest drags on the Nikkei.
IwaiCosmo strategist Kazuaki Shimada said the retreat was being driven mainly by overseas technology signals rather than a deterioration in Japan’s domestic economy.
Japanese corporate earnings could help change the direction of the market if companies deliver strong guidance.
The Nikkei’s price-weighted construction also magnifies movements in high-priced technology shares, helping explain why it fell more than twice as much as the capitalisation-weighted Topix.
The session was not a broad market capitulation.
Central Japan Railway rose 1.17% and East Japan Railway gained 0.6%, while Kawasaki Kisen and Mitsui OSK Lines also advanced. Otsuka Holdings climbed 1.6% to lead Nikkei gainers.
Those moves point to a rotation towards businesses with domestic revenues, steadier cash flows and less exposure to AI valuations.
Strong Japanese earnings could help separate local fundamentals from the global technology unwind. Another weak round of US chip results, however, would leave the Nikkei vulnerable to further selling.
Databricks and Microsoft extend strategic partnership through the 2030s to scale enterprise AI Databricks deepens its bet on Azure, growing its use of Azure Databricks to run its own core business operations and analytics, while both companies advance native integration across the Microsoft stack, including Databricks Genie and Microsoft 365 Databricks increases its use of Microsoft Azure Cobalt to improve performance and efficiency , /PRNewswire/ -- Microsoft Corp. and Databricks on Wednesday announced an expansion of their decade-long strategic partnership, extending into the 2030s. Databricks will deepen its use of Azure Databricks to run core business operations and build its unified lakehouse, while leveraging Azure Cobalt, Microsoft's next-generation Arm-based infrastructure, to improve performance and efficiency. Microsoft will also continue integrating Databricks Data and AI platform across its products, bringing capabilities like Genie, Databricks' AI co-worker, directly into customer workflows. Together, the companies are helping enterprises build AI grounded in their own business context with the cost efficiency, control and choice needed to scale successfully.
Enterprises want AI that understands their customers, products, operations, metrics and business processes, all while running securely where work happens. Yet, most still struggle to connect AI to trusted business knowledge, govern models and agents consistently, and control costs. Microsoft and Databricks are helping customers close that gap:
"For nearly a decade, Databricks and Microsoft have helped enterprises innovate with data and AI," said Ali Ghodsi, Co‑Founder and CEO of Databricks. "Today, our partnership is stronger than ever. With Databricks Genie and Unity AI Gateway deeply integrated across Microsoft's products, we're helping enterprises unify their data and ground AI in business knowledge. This lets customers get the full benefits of agents and models while controlling costs and ensuring governance."
"The next generation of AI will be defined by how effectively organizations turn their unique knowledge into intelligence," said Judson Althoff, CEO, Microsoft Commercial Business. "Microsoft and Databricks are helping customers connect data, AI and business context to accelerate decision-making and drive measurable impact. With Databricks deepening its investment in Azure Databricks and Azure Cobalt-powered infrastructure, customers will benefit from greater performance, efficiency and scale for their most demanding workloads. Databricks' decision to run its own core business operations on Azure Databricks also gives customers confidence in a platform proven at enterprise scale."
Databricks runs core business operations on Azure Databricks
As part of this latest deal, Databricks deepens its commitment to Azure, running its own core business operations and analytics on Azure Databricks, using the very platform it delivers to customers at scale.
Advancing performance with Azure Cobalt
Databricks will also expand its use of Azure Cobalt, Microsoft's next-generation Arm-based infrastructure, to improve performance and efficiency for agentic and data-intensive workloads. Databricks currently uses Cobalt 100 and plans to adopt Cobalt 200, which delivers up to 50% better performance and includes memory encryption enabled by default.
Deep integrations for Databricks Genie and Unity AI Gateway with Microsoft product stack
By combining the Databricks Data + AI Platform with Azure's global scale, customers can accelerate AI transformation while maintaining control and reliability. As a native Azure service, Azure Databricks makes its AI capabilities available directly within customers' existing Microsoft environment, grounding and operating agents on enterprise data with Genie and Genie Ontology, and governing models, agents and cost through Unity AI Gateway. Deeply integrated across the Microsoft ecosystem spanning Microsoft Entra, Azure Data Lake Storage, Azure security, Microsoft OneLake, Power BI, Microsoft Purview, Microsoft Foundry, Power Platform, Microsoft 365, Teams and Copilot, these capabilities bring governed, real-time data and AI into business workflows, giving organizations the context, control, choice and cost efficiency needed to drive impact.
Continued investment is evident from our recent announcements with Databricks at Data + AI Summit in June.
Customer impact with Azure Databricks
The deepened collaboration strengthens support for joint customers running data, analytics and AI workloads on Azure Databricks, delivering improved performance, security, AI governance and enterprise readiness. Thousands of customers, including Banco Bradesco, the Cincinnati Reds, Electrolux, SMBC and Unilever, already use Azure Databricks to run critical workloads and scale AI with confidence.
Read more on the proven business value of the Databricks and Microsoft partnership on the Microsoft Azure blog.
About Databricks
Databricks is the Data and AI company. More than 20,000 organizations worldwide — including AT&T, Bayer, BMW Group, HSBC, T-Mobile, Unilever, and 70% of the Fortune 500 — rely on Databricks Data + AI Platform to build and scale data and AI apps, analytics and agents. Headquartered in San Francisco with 30+ offices around the globe, Databricks offers a unified platform that includes Genie, Lakebase, Agent Bricks, Lakeflow, Lakehouse, and Unity Catalog. To learn more, follow Databricks on LinkedIn, X, YouTube, and Instagram.
About Microsoft
Microsoft (Nasdaq "MSFT" @microsoft) creates platforms and tools powered by AI to deliver innovative solutions that meet the evolving needs of our customers. The technology company is committed to making AI available broadly and doing so responsibly, with a mission to empower every person and every organization on the planet to achieve more.
Nvidia (NVDA -1.56%) is taking a larger equity position in Nebius (NBIS +1.29%).
*Stock prices used were the afternoon prices of July 21, 2026. The video was published on July 23, 2026.
Parkev Tatevosian, CFA has positions in Nvidia. The Motley Fool has positions in and recommends Nvidia. The Motley Fool has a disclosure policy. Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool.
Alphabet’s (GOOG -6.89%) (GOOGL -7.12%) YouTube has long been the leading user-created video platform, but the Google parent is so big that YouTube doesn’t get the same level of attention it would if it were a standalone company.
After all, YouTube makes up less than 10% of Alphabet’s revenue, and it pales in comparison to the massive Google Search business.
However, in the video entertainment arena, YouTube is a giant in its own right, and Netflix has long considered it its chief rival. YouTube just topped $10 billion in ad revenue in the second quarter for the first time ever, bringing in $11.1 billion in ad revenue, which doesn’t include subscriptions for YouTube Premium tiers.
At that level, YouTube is not far behind Netflix, which brought in $12.6 billion in total revenue in the second quarter.
Can YouTube catch the streaming leader? Let’s take a closer look.
Image source: Getty Images.
YouTube reported 12.8% revenue growth in the second quarter, slightly slower than Netflix’s 13.4%.
Netflix’s growth has slowed in recent quarters, and the stock has stumbled as investors worry about weak engagement, maturing markets, and its eagerness to make an acquisition, which suggests it is searching for its next growth leg. The streamer sees even slower growth in the third quarter, calling for an 11.7% increase in revenue.
YouTube’s growth rate has fluctuated within a similar range, between 9% and 21%, over the last ten quarters.
Though they have different business models, with Netflix charging a monthly fee to watch traditional television and movie programming, and YouTube selling ads alongside user-generated content, both platforms are highly profitable. Netflix reported an operating margin of 33.4% in the second quarter. Alphabet does not report operating margins for YouTube, but Wall Street analysts estimate it to be somewhere in the teens. YouTube shares revenue with content creators, which decreases its margins. Alphabet’s Google Services business, which is mostly made up of advertising, reported an operating margin of more than 40% in the second quarter.
Netflix and YouTube have also borrowed from each other’s playbooks in recent years. YouTube, once an entirely free service, has begun selling premium subscriptions for everything from music to traditional pay-TV to NFL Sunday TIcket.
Netflix, on the other hand, launched its advertising tier a few years ago, and it continues to be one of its strongest sources of growth for the company, and it’s aiming to double ad revenue from $1.5 billion to $3 billion this year.
A win-winNetflix’s lead over YouTube, though narrow, looks safe for now. While the two companies are competitors, there’s room in the market for both to succeed, as they serve different niches. Though Netflix sees all viewing time as competition, it’s often serving a different use case than YouTube.
Investors can’t invest directly in YouTube, but both of these platforms look poised for continued success and are likely to continue learning from each other. Expect both to continue delivering double-digit growth in the years ahead.
PURCHASE, N.Y.--(BUSINESS WIRE)--Mastercard announced a series of capability and control enhancements to its industry-leading virtual card number platform.
Not financial or tax advice. PANews content is strictly educational and informational and is not investment advice, financial advice, tax advice, legal advice, or a solicitation to buy or sell any digital asset, security, or financial product. Do your own research and consult qualified advisers.
Disclosure. PANews may publish sponsored content, partner content, advertisements, affiliate links, event promotions, and market commentary involving Web3 projects, service providers, or financial products. PANews personnel, contributors, or affiliates may hold digital assets or other interests related to covered topics. See our Terms of Service.
Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- Today, McDonald's Board of Directors declared a quarterly cash dividend of $1.86 per share of common stock payable on September 16, 2026 to shareholders of record at the close of business on September 1, 2026.
Upcoming Communications
For important news and information regarding McDonald's, including the timing of future investor conferences and earnings calls, visit the Investor Relations section of the Company's Internet home page at www.investor.mcdonalds.com. McDonald's uses this website as a primary channel for disclosing key information to its investors, some of which may contain material and previously non-public information.
About McDonald's
McDonald's is the world's leading global foodservice retailer with over 45,000 locations in over 100 countries. Approximately 95% of McDonald's restaurants worldwide are owned and operated by independent local business owners.
Forward-Looking Statements
This document contains certain forward-looking statements, which reflect management's expectations regarding future events and operating performance and speak only as of the date hereof. These forward-looking statements involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from expectations are detailed in the Company's filings with the Securities and Exchange Commission, including the Company's Form 10-Q filing for the quarter ended March 31, 2026. The Company undertakes no obligation to update such forward-looking statements, except as may otherwise be required by law.
MIAMI--(BUSINESS WIRE)--Starboard today announced the debut of an expansive collection of immersive retail experiences onboard Royal Caribbean's Legend of the Seas.
Luxury Travelers Embrace the Rejuvenating Power of Travel Through Wellness Experiences Rooted in Local Traditions
Oceania Vista® sailing in Santorini, Greece, and yoga and stretch classes aboard Oceania Cruises' ships. Download high-resolution images here. (Credit: Oceania Cruises®)
, /PRNewswire/ -- From practicing tai chi in Bangkok, to dance therapy in Colombo, to yoga and wine tasting in Santorini, Oceania Cruises®, the world's leading destination- and culinary-focused luxury cruise line, invites discerning travelers to embrace a new era of exploration through its acclaimed Wellness Discovery Tours.
Yoga classes offered on Oceania Cruises Responding to a growing interest in wellness experiences, Oceania Cruises offers more than 50 Wellness Discovery Tours in destinations throughout Asia, Europe and South America, as luxury travelers are increasingly seeking journeys that allow them to learn new skills and explore the world differently. This signature collection of tours offers opportunities to engage with centuries-old healing traditions, mindfulness practices and local cultures across the globe.
"Travel has become one of the most powerful ways people invest in their wellbeing. It's a means of stepping outside of their usual routine to slow down, explore different cultures and destinations, and return home with a renewed perspective," said Jason Montague, Chief Luxury Officer of Oceania Cruises. "Our Wellness Discovery Tours are designed for those seeking to nurture their wellbeing and discover the rejuvenating power of travel. For today's luxury guest, travel is much more than movement from place to place – it is a journey of discovery, with every voyage offering the chance to expand horizons, deepen understanding and return home transformed by new perspectives."
Intended to inspire connection and enrichment, Oceania Cruises' small-group, wellness-oriented tours bring guests together with local specialists and like-minded travelers. Experiences range from mineral-rich baths and yoga to dance, power walking and culinary classes.
These shoreside encounters are complemented by a wealth of enriching experiences on board Oceania Cruises' intimate, luxurious ships. With culinary lectures, hands-on cooking classes and food and beverage pairing experiences, plus creative workshops in the Artist Loft, insightful guest speakers and performances by local musicians, guests can enjoy a diverse program designed to enhance their journey.
The enrichment options both ashore and on board are encompassed by the serenity of the adults-only environment aboard Oceania Cruises' boutique ships, allowing guests to explore an extraordinary array of destinations at their own pace and with like-minded travelers.
Highlights of Oceania Cruises Wellness Discovery Tours:
Ultimate Traditional Dance Therapy – Colombo, Sri Lanka: Release tension and lift your mood through Kandyan dance, learning the moves and rituals of Sri Lanka's national dance in an uplifting group setting. Saigonese Organic Food Tasting – Ho Chi Minh City, Vietnam: Savor organic teas and vegetarian cuisine, engaging with local experts and gaining insights into Vietnam's celebrated tea culture. Tai Chi at Viharn Sien Park – Bangkok, Thailand: Visit a serene urban park in the shadow of the temple Viharn Sien to practice the slow, fluid movements of tai chi, an ancient form of exercise improving strength, flexibility and balance. Healthy Stroll Along the Cliffs and Getxo – Bilbao, Spain: Traverse geologically rich cliff paths, pass 18th-century windmills and fortresses, and experience the Basque fishing village of Getxo – with time to enjoy local tapas and authentic culture. Thermal Baths of the Popes – Rome (Civitavecchia), Italy: Restore mind and body at Terme dei Papi, soaking in mineral-rich waters beloved by popes, artists and poets for centuries, set in the inspirational Italian countryside. Traditional Chinese Medicine Experience – Hong Kong, China: Consult with a traditional medicine doctor and try therapies such as acupuncture or cupping, learning ancient methods to promote relaxation and vitality. Yoga & Wine Tasting Overlooking Caldera – Santorini, Greece: Find tranquility with a meditative yoga session on a winery terrace, followed by tastings of Santorini's distinct vintages while admiring the breathtaking views. Tai Chi & Vegetarian Lunch at a Monastery – Hanoi, Vietnam: Experience mindful movement surrounded by spectacular natural beauty and spiritual heritage in a Buddhist monastery on Yen Tu Mountain. Volcanic Thermal Pools and Naples – Naples/Pompeii, Italy: Alternate between hot and cold pools, surrounded by ancient landscapes and timeless healing traditions. Patagonian Hot Springs & Fjord Cruise – Puerto Chacabuco, Chile: Invite relaxation and mindfulness with a journey through the Aysén Fjord by catamaran to the secluded Ensenada Perez Hot Springs, where Patagonian landscapes surround naturally heated pools. Oceania Cruises is celebrated for its personalized service, award-winning cuisine and a crew-to-guest ratio designed for exceptional comfort. With destination-intensive itineraries ranging from seven to 180 days, guests return home with renewed energy, inspiration and stories that last a lifetime.
For more information visit OceaniaCruises.com or call 855-OCEANIA.
About Oceania Cruises®
Oceania Cruises® is the world's leading destination- and culinary-focused luxury cruise line, celebrated for its port-rich voyages and authentic cultural and culinary experiences. The line's intimate, luxurious ships feature an adults-only environment, with a high proportion of spacious rooms and suites, calling on more than 600 marquee and boutique ports in more than 100 countries across seven continents, with destination-intensive itineraries ranging from seven to 180 days. Aboard the designer-inspired ships, guests enjoy personalized service supported by a strong crew-to-guest ratio, alongside The Finest Cuisine at Sea®, prepared by one of the highest chef-to-guest ratios at sea. Oceania Cruises® is also recognized as one of the world's most awarded cruise lines, with accolades spanning luxury, dining, service and destination experiences. Oceania Cruises® has five Sonata Class ships on order scheduled for delivery in 2027, 2029, 2032, 2035 and 2037. Oceania Cruises® is a wholly owned subsidiary of Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH).
To add Benzinga News as your preferred source on Google, click here.
Posted In:
MarketsTrading IdeasPre-Market OutlookLong IdeasNewsEarningsEquitiesMarket SummaryStocks To Watch
Connect With Us
About Benzinga
About UsCareersAdvertiseContact UsMarket Resources
Advanced Stock Screener ToolsOptions Trading Chain AnalysisComprehensive Earnings CalendarDividend Investor Calendar and AlertsEconomic Calendar and Market EventsIPO Calendar and New ListingsMarket Outlook and AnalysisWall Street Analyst Ratings and TargetsTrading Tools & Education
Benzinga Pro Trading PlatformOptions Trading Strategies and NewsStock Market Trading Ideas and AnalysisTechnical Analysis Charts and IndicatorsFundamental Analysis and ValuationDay Trading Guides and StrategiesLive Investor EventsPre-market Stock Analysis and NewsCryptocurrency Market Analysis and NewsRing the Bell
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.
Charter Communications, Inc. (NASDAQ:CHTR) will release its second quarter earnings report before the opening bell on Friday, July 24.
Analysts expect the Stamford, Connecticut-based company to report quarterly earnings of $10 per share, up from $9.18 per share in the year-ago period. The consensus estimate for Charter Communications’ quarterly revenue is $13.51 billion. It reported $13.77 billion last year, according to Benzinga Pro.
On April 24, Charter Communications reported worse-than-expected first-quarter EPS results.
Charter Communications shares fell 2.1% to close at $126.50 on Thursday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.
Considering buying CHTR stock? Here’s what analysts think:
Photo via Shutterstock
Market News and Data brought to you by Benzinga APIs
Moneta Money Bank představila výsledky za 2Q 2026, v 10:00 se koná konferenční hovor. Čistý zisk za 2Q dosáhl 1,8 mld. Kč a management o 200 mil. Kč navýšil celoroční výhled. Výsledky hodnotíme neutrálně.
Výsledky hospodaření Moneta Money Bank za 2Q 2026 v mil. Kč 2Q 2026 Konsensus trhu 2Q 2025 Čisté úrokové výnosy 2 644 2 587 2 421 Čisté poplatky a provize 906 863 818 Ostatní provozní výnosy 142 175 173 Provozní výnosy 3 692 3 625 3 412 Provozní náklady (1 367) (1 387) (1 375) Provozní zisk 2 325 2 238 2 037 Náklady na riziko (254) (209) (117) Čistý zisk 1 763 1 718 1 628 Výsledky za 2Q 2026 Čisté úrokové výnosy ve 2Q dosáhly 2 644 mil. Kč, meziročně o 9 % více, mírně nad naším očekáváním ve výši 2 595 mil. Kč. Růst byl tažen především vyšším úvěrovým portfoliem.
Čisté úrokový výnosy Moneta Money Bank
Čisté poplatky a provize meziročně vzrostly o 11 % především díky distribuci investičních produktů.
Ostatní provozní výnosy naopak meziročně poklesly o 18 % na 142 mil. Kč.
Celkově tak Moneta za 2Q dosáhla provozních výnosů 3 692 mil. Kč, lehce nad naším očekáváním ve výši 3 632 mil. Kč.
Provozní náklady zůstaly meziročně na podobné úrovni, když vyšší mzdové náklady byly kompenzovány nižšími administrativními náklady a odpisy.
Provozní náklady Moneta Money Bank ve 2Q 2026
Na provozní úrovni banka reportovala zisk ve výši 2 325 mil. Kč při našem odhadu ve výši 2 253 mil. Kč.
Náklady na riziko v 2Q 2026 dosáhly výše 254 mil. Kč.
Celkově tak Moneta reportovala 8% meziroční růst čistého zisku na 1 763 mil. Kč, na úrovni našeho očekávání ve výši 1 765 mil. Kč.
Čistý zisk Moneta Money Bank za 2Q 2026
Čistý zisk za první polovinu letošního roku vzrostl na 3 346 mil. Kč, meziročně +8 %.
Čistý zisk Moneta Money Bank za 1H 2026
Klientské úvěry vzrostly o 9,1 % na 310 mld. Kč, zatímco klientské vklady vzrostly meziročně o 3,7 % na 454 mld. Kč.
Moneta dále reportovala kapitálovou přiměřenost 20 % a návratnost hmotného kapitálu (ROTE) 23,3 %.
Výhled Management potvrdil střednědobý výhled a pro letošní rok očekává, že dosáhne čistého zisku 6,8 mld. Kč, tedy o 200 mil. Kč více.
Střednědobý výhled Moneta Money Bank, zdroj: Moneta Money Bank
Hodnocení výsledkového reportu Čisté úrokové výnosy se meziročně zvýšily o 9 % a mírně předčily naše očekávání, když byly taženy velmi solidním růstem úvěrového portfolia. Management nadále drží provozní náklady pevně pod kontrolou. Provozní zisk byl mírně nad našimi odhady, naopak náklady na riziko vyšší, než jsme očekávali. Na úrovni čistého zisku Moneta dodala námi odhadovaných téměř 1,8 mld. Kč. Navýšení celoročního výhledu čistého zisku o 200 mil. Kč na 6,8 mld. Kč je v souladu s naší projekcí na letošní rok. Výsledkový report hodnotíme neutrálně.
Akcie Monety (BAAGECBA) včera uzavřely na pražské burze na 188,80 Kč a na RM-SYSTÉMu na 189 Kč.
Zdroj: Moneta Money Bank
Karel Nedvěd, Fio banka, a.s.
Související odkazy Projekce hospodaření Moneta Money Bank za 2Q 2026 Moneta: Komerční banka nastavila cílovou cenu na 192 Kč při doporučení „Držet“ Moneta: PKO BP Securities zvyšuje cílovou cenu ze 149 Kč na 200 Kč s novým doporučením "hold" Moneta Money Bank vydala nástroj vedlejšího kapitálu Tier 1 (AT1) Manažerské obchody: V květnu byl aktivní manažer Moneta Money Bank
Not financial or tax advice. PANews content is strictly educational and informational and is not investment advice, financial advice, tax advice, legal advice, or a solicitation to buy or sell any digital asset, security, or financial product. Do your own research and consult qualified advisers.
Disclosure. PANews may publish sponsored content, partner content, advertisements, affiliate links, event promotions, and market commentary involving Web3 projects, service providers, or financial products. PANews personnel, contributors, or affiliates may hold digital assets or other interests related to covered topics. See our Terms of Service.
TLDRAMD and Cerebras Build a Disaggregated AI Inference PlatformPlatform Targets Real Time AI ApplicationsDeployment Plans Expand AMD Helios AdoptionGet 3 Free Stock Ebooks AMD stock rebounds after unveiling a new AI inference partnership with Cerebras. Helios and Wafer-Scale Engine target faster AI responses with lower latency. Joint platform delivers up to 5x higher tokens per second per watt efficiency. Disaggregated architecture separates prompt processing from token generation. Cerebras Cloud will launch the combined AI solution in the second half of 2026. Advanced Micro Devices (AMD) shares closed at $539.69, down 2.29%, before rising 1.54% in after-hours trading to $548.00. The rebound followed the company’s announcement of a technical partnership with Cerebras Systems. The collaboration introduces a disaggregated AI inference platform built to improve speed, efficiency, and large-scale deployment.
Advanced Micro Devices, Inc., AMD
AMD and Cerebras Build a Disaggregated AI Inference Platform AMD partnered with Cerebras Systems to launch a new AI inference solution during Advancing AI 2026. The platform combines AMD Helios rackscale systems with the Cerebras Wafer-Scale Engine. The companies target higher inference performance across demanding enterprise workloads.
The joint platform separates prompt processing from token generation within a single inference workflow. AMD Helios manages high-throughput prompt execution and large context windows. The Cerebras Wafer-Scale Engine accelerates token generation with ultra-low latency.
The companies expect the combined architecture to deliver up to five times higher tokens per second per watt. This improvement increases processing efficiency while supporting demanding AI applications. As a result, the platform addresses performance and power requirements simultaneously.
Platform Targets Real Time AI Applications AI inference workloads now require different infrastructure for different computing tasks. Some deployments focus on maximum throughput for large request volumes. However, coding tools, autonomous agents, and live assistants require much faster response times.
The new platform assigns each workload stage to specialized hardware. AMD Helios processes prompts while maintaining high throughput across rack-scale deployments. The Cerebras Wafer-Scale Engine handles memory-intensive token generation with lower latency.
This architecture supports software development, robotics, scientific research and autonomous systems. Faster token generation improves response quality during interactive workloads. The combined platform addresses applications where processing speed directly affects system performance.
Deployment Plans Expand AMD Helios Adoption Cerebras plans to deploy AMD Helios systems across its data center infrastructure. The companies expect to introduce the joint offering through Cerebras Cloud during the second half of 2026. This deployment expands the commercial reach of AMD’s latest AI infrastructure.
The announcement strengthens AMD’s strategy to expand beyond AI training into inference computing. Demand for inference infrastructure continues growing as organizations deploy larger production AI systems. Therefore, hardware providers increasingly optimize platforms for specialized computing tasks instead of general-purpose processing.
The partnership also reflects broader industry adoption of heterogeneous computing architectures. Companies now combine specialized processors to improve efficiency across different AI workloads. AMD’s after-hours share rebound followed the announcement as the market reacted to the company’s expanded AI infrastructure strategy.
OCBC’s Sim Moh Siong and Christopher Wong note Gold has retreated back toward USD 4,040/4,050 after briefly trading above 4,160 as Brent surged past USD100 and the Dollar and US yields climbed. They say Gold’s tentative recoupling with geopolitical risk remains fragile, with the metal still trading mainly through the Oil and rates channel and facing two-way risks around nearby support and resistance.
Geopolitics outweighed by Oil and yields"Gold was unable to sustain its recent rebound, falling back toward 4040/50 levels after briefly trading above 4160 in the previous session."
"Gold fell back toward 4,040/50 levels as Brent broke above USD100 and both the USD and US yields moved higher, suggesting its tentative recoupling with geopolitical risk was not yet durable."
"Rather than benefiting from the renewed geopolitical risk, gold once again traded through the oil/rates channel."
"Losses were also broad-based across the precious metals complex, as silver, platinum and palladium fell. The reversal suggests the earlier signs of gold recoupling with geopolitical risk were not yet durable, with the metal remaining sensitive to further increases in oil, yields and rate expectations."
"Mild bullish momentum on daily chart intact but RSI fell. 2-way risks. Resistance at 4070 (21 DMA), 4167. Support at 4000, 3960 levels."
(This article was created with the help of an Artificial Intelligence tool and reviewed by an editor. Know more.)
MINNEAPOLIS--(BUSINESS WIRE)--Wizards, witches and Muggles alike can bring a little magic into their homes with new and returning Harry Potter-inspired products from Pillsbury and Betty Crocker. Arriving at retailers nationwide just in time for a season full of Harry Potter celebrations, this lineup is made for new ways to experience the beloved stories at home. With millions of fans around the globe, Harry Potter has become a cultural phenomenon that continues to bring families together. With.
In TRIUMPH-2, adults with obesity or overweight and type 2 diabetes, a population with increased difficulties losing weight, lost up to an average of 49.6 lbs (20.8%) at 80 weeks
In TRIUMPH-3, adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes, lost up to an average of 55.8 lbs (22.6%) at 80 weeks
Lilly plans to submit a Biologics License Application (BLA) for retatrutide to FDA in Q1 2027
, /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-2 and TRIUMPH-3, two pivotal Phase 3 trials evaluating retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist. In both studies, retatrutide met the primary endpoint, delivering substantial weight loss in adults with obesity and some of its most serious complications: type 2 diabetes and established cardiovascular disease.
"Across five positive Phase 3 studies, retatrutide has shown powerful efficacy, and we believe it could be an important future tool in the management of cardiometabolic health," said Kenneth Custer, Ph.D., executive vice president and president, Lilly Cardiometabolic Health. "With the positive results from TRIUMPH-2 and TRIUMPH-3, we now have the clinical data package to support global submissions for retatrutide as a potential treatment for obesity, knee osteoarthritis pain, and obstructive sleep apnea. We look forward to working with regulators as they evaluate this first-of-its-kind medicine."
In TRIUMPH-2, all three studied doses of retatrutide (4 mg, 9 mg, and 12 mg) delivered substantial weight loss and improved glycemic control at 80 weeks in adults with type 2 diabetes and obesity or overweight. Participants taking retatrutide 4 mg, 9 mg, and 12 mg lost an average of 29.8 lbs (12.7%), 45.4 lbs (19.1%), and 49.6 lbs (20.8%), respectively, alongside A1C reductions of up to an average of 1.6%.
TRIUMPH-2 Efficacy Estimand Results in Participants with Obesity and Type 2 Diabetes1
Primary Endpoint at 80 Weeks
Retatrutide 4 mg
Retatrutide 9 mg
Retatrutide 12 mg
Placebo
Percent change in body weight from avg. baseline of 106.4 kg (234.6 lbs; BMI of 38.2 kg/m²)i
-12.7% (-13.5 kg; -29.8 lbs)
-19.1% (-20.6 kg; -45.4 lbs)
-20.8% (-22.5 kg; -49.6 lbs)
-4.0% (-4.2 kg; -9.3 lbs)
Key Secondary Endpoint at 80 Weeks
Change in A1C from a baseline of 7.7%
-1.4%
-1.6%
-1.5%
-0.2%
iPercent body weight reduction with retatrutide 4 mg was a key secondary endpoint.
In TRIUMPH-3, both studied doses of retatrutide (9 mg and 12 mg) delivered substantial weight loss in adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes. Participants lost up to an average of 55.8 lbs (22.6%) at 80 weeks.
In the study, major adverse cardiovascular events (MACE) occurred less frequently than anticipated in both retatrutide and placebo arms. In pre-specified analyses for time to first occurrence of MACE, there were 44 MACE-5 (all-cause death, heart attack, stroke, heart failure event, or coronary revascularization) events observed in participants randomized to retatrutide (pooled 9 mg and 12 mg) and 52 events observed in those randomized to placebo, resulting in a hazard ratio of 0.82 (95.0% CI: 0.55 to 1.22). There were 27 MACE-3 (cardiovascular death, heart attack, or stroke) events in participants randomized to retatrutide and 23 in those randomized to placebo, resulting in a hazard ratio of 1.12 (95.0% CI: 0.64 to 1.96).
In TRIUMPH-3, retatrutide meaningfully reduced certain cardiovascular risk factors, with the highest dose delivering average reductions of 37.0% in triglycerides, 16.5% in non-HDL cholesterol, 9.3 mmHg in systolic blood pressure, 7.5 in (19.0 cm) in waist circumference, and 51.2% in high-sensitivity C-reactive protein (hsCRP).
TRIUMPH-3 Efficacy Estimand Results in Participants with Severe Obesity and Established Cardiovascular Disease1
Primary Endpoint at 80 Weeks
Retatrutide 9 mg
Retatrutide 12 mg
Placebo
Percent change in body weight from avg. baseline of 111.4 kg (245.6 lbs; BMI of 40.4 kg/m²)
-21.6% (-23.9 kg; -52.7 lbs)
-22.6% (-25.3 kg; -55.8 lbs)
-3.2% (-3.5 kg; -7.7 lbs)
Additional Analysesi
In-Study
On-Treatment
Time to first occurrence of MACE-5
Hazard ratio = 0.82
95.0% CI: 0.55 to 1.22
Hazard ratio = 0.73
95.0% CI: 0.47 to 1.12
Time to first occurrence of MACE-3
Hazard ratio = 1.12
95.0% CI: 0.64 to 1.96
Hazard ratio = 0.92
95.0% CI: 0.51 to 1.65
iHazard ratio was estimated from Cox proportional hazards model comparing retatrutide (pooled 9 mg and 12 mg) vs. placebo; in-study analysis (pre-specified) includes events which occurred during the study treatment period regardless of adherence to retatrutide or placebo, while on-treatment analysis (not pre-specified) excludes events which occurred more than 35 days after discontinuing retatrutide or placebo.
In TRIUMPH-2, the most common adverse events with retatrutide (4 mg, 9 mg, 12 mg vs. placebo, respectively) were diarrhea (27.4%, 33.5%, 33.6% vs. 13.2%), nausea (13.7%, 20.8%, 28.0% vs. 8.0%), constipation (14.0%, 16.2%, 16.8% vs. 9.4%), decreased appetite (5.8%, 12.3%, 17.1% vs. 4.5%), and vomiting (5.5%, 10.2%, 15.7% vs. 4.2%). In TRIUMPH-3, the most common adverse events with retatrutide (9 mg, 12 mg vs. placebo, respectively) were diarrhea (30.1%, 24.4% vs. 8.7%), nausea (21.7%, 22.4% vs. 5.8%), constipation (18.0%, 15.7% vs. 7.1%), decreased appetite (13.5%, 14.5% vs. 3.0%), and hyperglycemia (3.9%, 3.1% vs. 13.4%). In TRIUMPH-2, the incidence of dysesthesia and urinary tract infections were 4.5%, 5.6%, 7.3% vs. 0.7% and 3.8%, 6.3%, 8.0% vs. 6.6% with retatrutide 4 mg, 9 mg, 12 mg vs. placebo, respectively. In TRIUMPH-3, the incidence of dysesthesia and urinary tract infections were 6.4%, 6.4% vs. 1.3% and 6.1%, 7.0% vs. 5.3% with retatrutide 9 mg, 12 mg vs. placebo, respectively. These events were generally mild to moderate, and the majority resolved during treatment. Discontinuation rates due to adverse events in TRIUMPH-2 were 3.8% (4 mg), 11.6% (9 mg), and 7.7% (12 mg) with retatrutide, compared with 4.9% for placebo. Discontinuation rates due to adverse events in TRIUMPH-3 were 9.8% (9 mg) and 13.5% (12 mg) with retatrutide, compared with 4.8% for placebo.
Detailed results from TRIUMPH-2 and TRIUMPH-3 will be presented at future medical meetings and published in peer-reviewed journals. Lilly is completing the comprehensive Chemistry, Manufacturing, and Controls (CMC) data package required for a Biologics License Application (BLA) and plans to subsequently submit retatrutide in Q1 2027 for U.S. approval.
About retatrutide
Retatrutide is an investigational, once-weekly, triple hormone receptor agonist. Retatrutide is a single molecule that activates the body's receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. Lilly is studying retatrutide in several Phase 3 clinical trials to evaluate its potential efficacy and safety in obesity and overweight with at least one weight-related medical problem, type 2 diabetes, knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, chronic low back pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease. Retatrutide is an investigational molecule that cannot be legally sold or marketed for human use.
About TRIUMPH-2, TRIUMPH-3, and the TRIUMPH clinical trial program
TRIUMPH-2 (NCT05929079) is a Phase 3, 80-week, randomized, double-blind, and placebo-controlled trial under a basket design investigating the efficacy and safety of retatrutide once weekly compared with placebo in participants with type 2 diabetes and obesity or overweight. The study randomized 1,152 participants in a 1:1:1:1 ratio to receive retatrutide 4 mg, 9 mg, 12 mg, or placebo. Participants randomized to retatrutide initiated treatment with 2 mg once weekly and increased the dose in a stepwise approach every four weeks until reaching the target dose of 4 mg (via steps at 2 mg and 4 mg), 9 mg (via steps at 2 mg, 4 mg, and 6 mg) or 12 mg (via steps at 2 mg, 4 mg, 6 mg, and 9 mg). TRIUMPH-2 included a post-treatment follow-up period of four weeks.
TRIUMPH-3 (NCT05882045) is a Phase 3, 80-week, randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of retatrutide once weekly compared with placebo in participants with severe obesity (Class 2 or Class 3), defined as BMI ≥35 kg/m2, and established cardiovascular disease. The study randomized 1,949 participants in a 1:1:2 ratio to receive retatrutide 9 mg, 12 mg, or placebo. Participants randomized to retatrutide initiated treatment with 2 mg once weekly and increased the dose in a stepwise approach every four weeks until reaching the target dose of 9 mg (via steps at 2 mg, 4 mg, and 6 mg) or 12 mg (via steps at 2 mg, 4 mg, 6 mg, and 9 mg).
The initial TRIUMPH Phase 3 clinical development program is evaluating the safety and efficacy of retatrutide for the treatment of patients with obesity or overweight, moderate-to-severe obstructive sleep apnea and obesity, and knee osteoarthritis pain across four global registrational trials. The program, which began in 2023, enrolled more than 5,800 participants.
Endnotes:
The efficacy estimand represents efficacy had all randomized participants remained on study intervention (with possible dose interruptions and modifications) without initiating prohibited weight management treatments (and glycemic rescue therapy for glycemic endpoints only). FOUNDAYO INDICATION AND SAFETY SUMMARY WITH WARNINGS
Foundayo (fown-DAY-oh) is a prescription medicine used with a reduced-calorie diet and increased physical activity to help adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off.
Foundayo should not be used with other GLP-1 receptor agonist medicines. It is not known if Foundayo is safe and effective for use in children. Warnings – Foundayo may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.
Do not use Foundayo if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC). Do not use Foundayo if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Do not use Foundayo if you have had a serious allergic reaction to orforglipron or any of the ingredients in Foundayo. Foundayo may cause serious side effects, including:
Inflammation of the pancreas (pancreatitis). Stop taking Foundayo and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. Sometimes you may feel the pain from your abdomen to your back.
Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Foundayo. Tell your healthcare provider if you have stomach problems that are severe or will not go away.
Dehydration leading to kidney problems. Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away.
Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Foundayo with medicines that can cause low blood sugar, such as an insulin or sulfonylurea. Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness, or feeling jittery.
Serious allergic reactions. Stop using Foundayo and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat.
Changes in vision in patients with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Foundayo.
Gallbladder problems. Gallbladder problems have happened in some people who use Foundayo. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), or clay-colored stools.
Food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Foundayo may increase the chance of food getting into your lungs during surgery or other procedures. Tell your healthcare providers that you are taking Foundayo before you are scheduled to have surgery or other procedures.
Common side effects
The most common side effects of Foundayo include nausea, constipation, diarrhea, vomiting, indigestion, stomach (abdominal) pain, headache, swollen belly, feeling tired, belching, heartburn, gas, and hair loss. These are not all the possible side effects of Foundayo. Talk to your healthcare provider about any side effect that bothers you or doesn't go away.
Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.
Before taking Foundayo
Tell your healthcare provider about all the medicines you take. Foundayo may affect the way some medicines work, and some medicines may affect the way Foundayo works. Pregnancy Exposure Registry: There will be a pregnancy exposure registry for women who have taken Foundayo during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry, or you may contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979). If you take birth control pills by mouth, talk to your healthcare provider before you take Foundayo. Birth control pills may not work as well while taking Foundayo. Your healthcare provider may recommend another type of birth control for 30 days after starting Foundayo and for 30 days after each dose increase of Foundayo. Talk to your healthcare provider about low blood sugar and how to manage it. Tell your healthcare provider if you are taking medicines to treat diabetes including an insulin or sulfonylurea. Review these questions with your healthcare provider:
❑ Do you have other medical conditions, including problems with your pancreas or kidneys, or severe problems with your liver, severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting food?
❑ Do you have a history of diabetic retinopathy?
❑ Are you scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)?
❑ Are you pregnant or plan to become pregnant? Foundayo may harm your unborn baby.
❑ Are you breastfeeding or plan to breastfeed? Breastfeeding is not recommended during treatment with Foundayo.
❑ Do you take any other prescriptions or over-the-counter medicines, vitamins, or herbal supplements?
How to take
Take Foundayo exactly as your healthcare provider tells you to. Use Foundayo with a reduced-calorie diet and increased physical activity. Take Foundayo by mouth 1 time each day, with or without food. Swallow tablets whole. Do not break, crush, or chew the tablet. If you miss a dose, take it as soon as possible. Do not take 2 doses of Foundayo in the same day. Do not take more than 1 tablet per day. If you miss taking Foundayo for 7 or more days in a row, call your healthcare provider to talk about how to restart your treatment. If you take too much Foundayo, call your healthcare provider or Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away. Learn more
Foundayo is a prescription medicine available in 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, or 17.2 mg oral tablets. For more information, call 1-800-545-5979 or go to foundayo.lilly.com.
ZEPBOUND INDICATIONS AND SAFETY SUMMARY WITH WARNINGS
Zepbound® (ZEHP-bownd) is an injectable prescription medicine used with a reduced-calorie diet and increased physical activity to help adults with:
obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off. moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA. Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines. It is not known if Zepbound is safe and effective for use in children.
Warnings - Zepbound may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.
• Do not use Zepbound if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC).
• Do not use Zepbound if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Do not use Zepbound if you have had a serious allergic reaction to tirzepatide or any of the ingredients in Zepbound.
KwikPen®: Do not share your KwikPen with other people, even if the pen needle has been changed. You may give other people a serious infection or get a serious infection from them.
Zepbound may cause serious side effects, including:
Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Zepbound. Tell your healthcare provider if you have stomach problems that are severe or will not go away.
Dehydration leading to kidney problems. Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away.
Gallbladder problems. Gallbladder problems have happened in some people who use Zepbound. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), or clay-colored stools.
Inflammation of the pancreas (pancreatitis). Stop using Zepbound and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. You may feel the pain from your abdomen to your back.
Serious allergic reactions. Stop using Zepbound and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat.
Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Zepbound with medicines that can cause low blood sugar, such as a sulfonylurea or insulin. Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness or feeling jittery.
Changes in vision in patients with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Zepbound.
Food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep
sleepiness (deep sedation). Zepbound may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your healthcare providers that you are taking Zepbound before you are scheduled to have surgery or other procedures.
Common side effects
The most common side effects of Zepbound include nausea, diarrhea, vomiting, constipation, stomach (abdominal) pain, indigestion, injection site reactions, feeling tired, allergic reactions, belching, hair loss, and heartburn. These are not all the possible side effects of Zepbound. Talk to your healthcare provider about any side effect that bothers you or doesn't go away.
Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.
Before using Zepbound
Your healthcare provider should show you how to use Zepbound before you use it for the first time. Talk to your healthcare provider about low blood sugar and how to manage it. Tell your healthcare provider if you are taking medicines to treat diabetes including an insulin or sulfonylurea. If you take birth control pills by mouth, talk to your healthcare provider before you use Zepbound. Birth control pills may not work as well while using Zepbound. Your healthcare provider may recommend another type of birth control for 4 weeks after you start Zepbound and for 4 weeks after each increase in your dose of Zepbound. Review these questions with your healthcare provider:
❑ Do you have other medical conditions, including problems with your pancreas, or severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting food?
❑ Do you take diabetes medicines, such as insulin or sulfonylureas?
❑ Do you have a history of diabetic retinopathy?
❑ Are you scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)?
❑ Do you take any other prescription medicines or over-the-counter drugs, vitamins, or herbal supplements?
❑ Are you pregnant, plan to become pregnant, breastfeeding, or plan to breastfeed? Zepbound may harm your unborn baby. Tell your healthcare provider if you become pregnant while using Zepbound. Zepbound may pass into your breast milk. You should talk with your healthcare provider about the best way to feed your baby while using Zepbound.
Pregnancy Exposure Registry: There will be a pregnancy exposure registry for women who have taken Zepbound during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry, or you may contact Lilly at 1-800-LillyRx (1-800-545-5979). How to take
Read the Instructions for Use that come with Zepbound. Use Zepbound exactly as your healthcare provider says. Use Zepbound with a reduced-calorie diet and increased physical activity. Inject Zepbound under the skin (subcutaneously) of your stomach (abdomen), thigh, or have another person inject in the back of the upper arm. Do not inject ZEPBOUND into a muscle (intramuscularly) or vein (intravenously). Use Zepbound 1 time each week, at any time of the day. Change (rotate) your injection site with each weekly injection. Do not use the same site for each injection. If you take too much Zepbound, call your healthcare provider, call the Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away.
Zepbound is approved as a 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg injection.
Learn more
Zepbound is a prescription medicine. For more information, call 1-800-LillyRx (1-800-545-5979) [or goto www.zepbound.lilly.com].
This summary provides basic information about Zepbound but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your healthcare provider. Be sure to talk to your healthcare provider about Zepbound and how to take it. Your healthcare provider is the best person to help you decide if Zepbound is right for you.
ZP CON BS 25FEB2026
Zepbound®, its delivery device base and KwikPen® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.
About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. P-LLY
Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about retatrutide as a potential treatment for adults with type 2 diabetes and obesity or overweight and adults with severe obesity and established cardiovascular disease, and the timeline for future readouts, presentations and other milestones relating to retatrutide and its clinical trials and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development and commercialization. Among other things, there is no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with expectations or study results to date, that retatrutide will prove to be a safe and effective treatment for type 2 diabetes, obesity or other potential indications, that retatrutide will receive regulatory approval, or that Lilly will execute its strategy as expected. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.
Refer to: Niki Biro; [email protected] (Media)
Michael Czapar; [email protected] (Investors)
Some stocks look too attractive to pass up, given their incredibly strong businesses and excellent prospects. In my view, that's the case with Eli Lilly (LLY +1.92%) and Intuitive Surgical (ISRG -2.47%), two healthcare companies. These stocks have delivered excellent returns over the past decade, but neither has peaked yet. Here is why Eli Lilly and Intuitive Surgical are outstanding stocks to buy.
Image source: The Motley Fool.
1. The weight loss leader Obesity is considered an epidemic. It affects a significant percentage of the population, particularly in the U.S., where about 40% of adults are obese, according to the U.S. Centers for Disease Control and Prevention. Obesity is linked to dozens of diseases and costs the U.S. healthcare system tens of billions of dollars every year. For all these reasons, the market for weight management medicines is growing rapidly, and Eli Lilly is currently the leader in this niche.
The company's approved portfolio features Zepbound, a subcutaneous anti-obesity drug, and Foundayo, an oral pill. Both are performing well and helping Eli Lilly grow its revenue much faster than its similarly sized peers in the pharmaceutical industry.
LLY Revenue (Quarterly YoY Growth) data by YCharts
However, Eli Lilly will start facing more competition in this area over the next few years. Not to worry: The company is working hard on next-gen weight-loss therapies, some of which could be even better than its current ones.
Today's Change
(
1.92
%) $
22.27
Current Price
$
1,185.28
Eli Lilly is looking to expand the market, as it did with Foundayo, which is attracting mostly brand-new patients. The company's newer, differentiated medicines might do the same. Eli Lilly's retatrutide, for instance, recently posted an average weight loss of up to 20.8% in patients with type 2 diabetes who were overweight or obese in an 80-week phase 3 study.
That's impressive considering people with diabetes have a harder time losing weight, but retatrutide could be highly effective at helping them do so, largely thanks to the fact that it works by activating three natural hormone pathways (compared to either one or two for most approved therapies) that help people eat less, burn more calories, and better control their blood sugar.
Retatrutide is just one example of Eli Lilly's deep pipeline in this area, which could help it ride the weight-loss tailwind over the next five years. And even beyond this market, Eli Lilly has a large pipeline in other areas, as well as other blockbusters in its approved portfolio. Eli Lilly has been one of the top-performing pharmaceutical giants in recent years, and should remain so. The stock is a no-brainer buy.
2. The sell-off is overdone Intuitive Surgical has faced headwinds in recent years, including increased competition, tariffs, and lower margins on the newest version of its da Vinci surgical system. The company's shares have significantly underperformed the broader market, declining by 33% over the past 12 months. However, Intuitive Surgical's medium-term prospects remain strong, making the current dip a buying opportunity.
Here's why the business is still healthy. Intuitive Surgical's launch of the da Vinci 5 has been hugely successful and presents the company with attractive opportunities, despite its lower margins. This new device lets surgeons feel how much force they're using and runs on a far more powerful computer, advantages which, over time, could enable smarter software, artificial intelligence-assisted surgery, fewer mistakes, and better patient outcomes.
Today's Change
(
-2.47
%) $
-8.40
Current Price
$
332.29
That means additional indications, eventually, and potentially, greater adoption of robotic-assisted surgery (RAS). So, the da Vinci 5's lower margins are worth it once we zoom out and focus on the company's long-term opportunities. It could also help Intuitive Surgical stay ahead of the new competition. The company's da Vinci system already has more than two decades of real-world outcomes to back it up, but it's important to continue innovating, which is what it did with the da Vinci 5.
Further, Intuitive Surgical benefits from a wide moat due to high switching costs, as its expensive devices, which also have a steep learning curve, become far too valuable for hospitals to replace with competitors' devices. That grants the company pricing power, which it might lean on to mitigate the impact of tariffs on its financial results. Intuitive Surgical's stock may remain volatile over the next year or so, but in five years, it could be far above its current levels. Patience will be rewarded.
Not every cheap stock is necessarily one worth owning. If you can find the right high-quality, high-yield tickers that are only temporarily beaten down, however, cheap stocks are actually bargains just waiting to be bought.
Here's a rundown of three dirt cheap dividend payers most investors are simply overlooking. That spells opportunity for you.
Novo Nordisk It's not too difficult to figure out why Novo Nordisk (NVO -0.02%) shares are down so much from their 2024 peak. The GLP-1 weight-loss drug race that it helped start has since turned incredibly competitive, so much so that Novo's now losing market share to rival Eli Lilly (LLY +1.92%) (and others) within a business it largely built, forcing price cuts. Investors are also concerned about the limited expansion of Wegovy's label in this environment.
More recently, Novo's decision to file a lawsuit against Lilly (claiming that its top competitor's GLP-1 drug's advertising is misleading) may be valid, but it also suggests a certain degree of concerning desperation. Never even mind the fact that 2026 is now being seen as a "reset" year far sooner than a reset should have been necessary for the company.
Today's Change
(
-0.02
%) $
-0.01
Current Price
$
48.18
However, with the stock now down more than 60% from its mid-2024 high and still within sight of a recently reached five-year low -- and priced at less than 12 times its trailing earnings -- the sellers have arguably overshot their target. They've priced in all of these problems, and then some, without factoring in the fact that Wegovy is still a powerful brand in all of its present and future forms.
That's not the crux of the reason to consider stepping into a position in NVO here and now, however. Rather, the top reason to take a closer look at the beaten-down name at this time is its dividend yield, which currently stands at a little over 3.6% on a forward-looking basis. At the very least, the cash flow supporting these dividend payments will remain intact while the company works through its reset and continues working on the 32 drug trials it's currently got underway, nine of which are now in phase 3.
PepsiCo Novo Nordisk isn't the only attractive dividend name currently dancing with a new 52-week low. Snack food and beverage powerhouse PepsiCo's (PEP -0.52%) shares are in a similar situation. The stock's down 20% from its early February peak, dragging its forward-looking price-to-earnings ratio down to a multiyear low of less than 16, and pumping its forward-looking dividend yield up to 4.4%.
This weakness makes superficial sense. Organic revenue growth remains at a tepid 2.5% pace, bogged down by its North American food business. Cost and health concerns are both contributing factors to this headwind. Meanwhile, last quarter's core operating margin of 16.8% was down 40 basis points from the year-ago comparison, as the company is using price cuts to prop up demand however and whenever it can. Several analysts lowered their price targets on PEP following the release of its Q2 results as well. Investors are understandably nervous.
Image source: Getty Images.
There's nothing PepsiCo is going through now that it hasn't been through and survived before. Although its stock doesn't necessarily recover very quickly from these sorts of setbacks (since the economic underpinnings are also slow-moving), it's now 20% below February's high and down more than 30% from its 2023 peak. This recent weakness is a great opportunity to step into a long-term position in a quality blue chip.
It's a quality blue chip, by the way, that's now raised its dividend for 54 consecutive years. That streak isn't likely to end anytime soon.
Accenture Last but not least, add Ireland-based Accenture Plc (ACN -0.96%) to your list of cheap dividend stocks to buy if you've got $1,000 -- or any other amount -- you're looking to put to work generating income.
It's not a household name, although there's a good chance you or someone in your household benefits from its work. Accenture offers a number of specialized business services, ranging from cybersecurity to supply chain optimization to technology overhauls to risk management. It's serving markets like banks, travel, retail, healthcare, utilities, and more. The company did $69.7 billion in sales last fiscal year, up 7.4% year over year, and is likely to report comparable growth again for the fiscal year ending in August.
Unfortunately, this growth wasn't enough to stave off the 64% setback this stock has suffered since February of last year. You can probably guess why. Investors are fearful that artificial intelligence will eventually be able to replicate much of what this company brings to the table -- and perhaps it will.
Today's Change
(
-0.96
%) $
-1.35
Current Price
$
138.74
As time marches on, however, institutions are learning that AI can't do everything, and too much of what it can do, it doesn't do particularly well. Companies still need plenty of actual people to make experienced judgment calls and apply good common sense that artificial intelligence platforms often just don't have. This is good news for Accenture, and by extension, for its shareholders. It's just not yet evident in the form of a rebound in the stock.
That doesn't mean you have time to wait if you're interested, though. Priced at only 10 times this year's expected per-share profit and with a forward-looking dividend yield of 4.6%, this ticker's apt to fall back into favor sooner rather than later.
Analysts think so, anyway. Their consensus price target of $175.41 is 25% above the stock's present price.
Not financial or tax advice. PANews content is strictly educational and informational and is not investment advice, financial advice, tax advice, legal advice, or a solicitation to buy or sell any digital asset, security, or financial product. Do your own research and consult qualified advisers.
Disclosure. PANews may publish sponsored content, partner content, advertisements, affiliate links, event promotions, and market commentary involving Web3 projects, service providers, or financial products. PANews personnel, contributors, or affiliates may hold digital assets or other interests related to covered topics. See our Terms of Service.
Strategy (MSTR -6.38%) was a huge winner from 2024 through 2025 as it aggressively issued stock and debt to fund Bitcoin purchases. As Bitcoin's price continued to rise, Strategy's massive stockpile soared in value, allowing the company to easily raise more capital, creating a powerful cycle that amassed an enormous Bitcoin stockpile.
Things have changed, though. Bitcoin's price has fallen nearly halfway from its peak last year, and Strategy hasn't been buying the dip lately. Strategy's latest 8-K filing shows that it hasn't purchased any Bitcoin for four consecutive weeks. Instead, it is selling stock to raise funds, increasing its cash reserves to $3.2 billion.
Should investors be concerned about buying Strategy stock amid the company's sudden pivot? Here's what you need to know.
Image source: The Motley Fool.
Fortifying the balance sheet isn't a bad thing Bitcoin is infamously volatile, so a steep decline was probably only a matter of time. It's one thing for an individual investor to buy into a dip, but Strategy is an enormous company with billions of dollars of assets. Opportunistic buying would be nice, but Strategy is focusing on strengthening its balance sheet and preparing for a scenario where Bitcoin continues to decline.
Strategy has 843,775 BTC at an average cost of $75,476 per token. That means that the company is currently sitting on paper losses. It has cash obligations in the form of interest payments on its debt and dividends paid out to preferred shares. Nobody can predict prices, so there's no telling how much lower Bitcoin might go or when it rebounds, or if it ever does.
Holding more cash provides a safety buffer from nightmare situations, such as having to sell at a loss to meet its obligations.
Today's Change
(
-6.38
%) $
-6.38
Current Price
$
93.63
But it does expose a flaw in Strategy's business model Strategy's recent pause in buying Bitcoin makes sense, but it raises some concerns. As a Bitcoin treasury, Strategy could maximize value for shareholders by accumulating Bitcoin at the lowest possible cost basis. If Strategy's playbook of raising money and buying Bitcoin only works when prices go up, that's a potential red flag.
In that case, it's fair to wonder what value Strategy's current business model can generate, other than functioning as a leveraged bet on rising Bitcoin prices. Remember, Strategy primarily issues debt and stock to fund BTC purchases. Issuing stock dilutes existing shareholders, and doesn't work nearly as well at lower share prices because it takes more shares and dilution to raise the same amount of capital.
Strategy is smart to fortify its balance sheet, but a prolonged decline in Bitcoin is still a massive threat to the business. At the end of the day, investors might be better off owning Bitcoin themselves or investing in a spot Bitcoin ETF.
OMAHA, Neb. & MONTREAL--(BUSINESS WIRE)--Union Pacific Railroad (NYSE: UNP) and CN (NYSE: CNI) today announced the signing of a binding Memorandum of Understanding that will strengthen rail service across North America, improving both railroads' ability to serve customers. The agreement provides Union Pacific with expanded operating rights over CN's Elgin, Joliet & Eastern Railway (EJ&E) corridor through Chicago, while granting CN new rights over Union Pacific's network between Memphis,.
Injective (INJ) remains in a recovery phase despite a mild daily decline, with technical indicators signaling renewed buying interest. The INJ token now benefits from improved accessibility after its integration with Coinbase, boosting exposure as traders monitor key resistance levels.
Technical outlook and key price levelsINJ is currently trading at $5.16, accompanied by a 24-hour trading volume of $62.96 million and a market capitalization of $513.67 million. Although the token posted a 2.08% drop in value over the past 24 hours, its price structure suggests the possibility of a near-term bullish reversal.
Abundance, a crypto analyst, observed that INJ has rebounded from a recent bottom at $4.45 and is forming a series of higher highs and higher lows on the daily chart. This pattern, combined with the token’s movement above a rising moving average, reinforces market optimism. Abundance highlighted the $5.05–$5.10 range as critical short-term support, reflecting growing buyer confidence.
The recent upward move stalled at the $5.30–$5.40 range due to increased selling pressure. Nevertheless, subdued candle bodies suggest consolidation rather than a significant reversal. If INJ remains above $5.05, analysts expect another attempt to challenge the next supply zone near $5.84, which now stands as the principal resistance.
Holding above the $5.05 line could encourage another test of the $5.84 supply zone, while a decisive break above $5.84 may set the stage for further gains toward $6.50. Conversely, a decline below $5.05 could lead to a retreat to support levels at $4.85, $4.60, and $4.45.
Price LevelRole$5.05–$5.10Immediate support$5.30–$5.40Short-term resistance$5.84Major resistance$6.50Key resistance/target$4.85/$4.60/$4.45Support levels on breakdownCoinbase integration and ecosystem expansionAccording to Injective, native INJ is now officially available on Coinbase. This integration gives Coinbase users the ability to deposit, withdraw, and trade INJ directly, streamlining participation in the Injective ecosystem. As the largest US-based cryptocurrency exchange by trading volume, Coinbase’s support is expected to boost awareness and liquidity for the INJ token.
Injective is a layer-1 blockchain focused on building decentralized finance (DeFi) applications, enabling cross-chain trading and robust interoperability between networks. The protocol allows developers to create exchanges, derivatives, and other financial products with strong performance and minimal fees.
Mini dictionary: Injective is a decentralized blockchain protocol designed for finance, providing a platform for building dApps focused on trading, derivatives, lending, and more. It is optimized for cross-chain interoperability and low fees, attracting DeFi projects that require customizable modules for financial services.
The partnership with Coinbase simplifies movement of assets into the Injective protocol and is anticipated to spark increased involvement in the token ecosystem. As more exchanges introduce direct support for native INJ, the project expects to benefit from expanded liquidity and broader participation.
Native INJ is now live on Coinbase, and users can seamlessly transfer the asset between Coinbase and the Injective ecosystem through direct deposits and withdrawals, giving traders improved accessibility and flexibility.
Market context and outlookDespite the market optimism and fresh exchange listing, INJ continues to face downward pressure, reflecting broader weakness in the cryptocurrency market. Bitcoin (BTC) has also started to trend lower, which has contributed to recent soft performance in INJ and similar tokens.
Analysts have issued positive technical outlooks based on Injective’s recovery from local lows, but emphasize that market conditions remain volatile. Price movements may continue to mirror trends in leading digital assets until INJ establishes a decisive move above major resistance levels.
Disclaimer: The information contained in this article does not constitute investment advice. Investors should be aware that cryptocurrencies carry high volatility and therefore risk, and should conduct their own research.
The Australian Dollar (AUD) trades marginally higher at around 0.6976 against the US Dollar (USD) during the European trading session on Friday. The Aussie pair edges up, but is broadly weak, as surging US Treasury yields due to the revival of hawkish Federal Reserve (Fed) interest rate expectations dampens investors’ risk appetite.
As of writing, 10-year US Treasury Yields trade firmly at around 4.70%, the highest level seen in over 18 months. S&P 500 futures trade cautiously near Thursday’s low at around 7,404, reflecting a risk-off market mood.
According to the CME FedWatch tool, the odds of the Fed delivering an interest rate hike in the policy meeting next week stand at 33.7%, significantly higher than 11.8% recorded last week. Fed’s interest rate hike prospects were also higher at around 34% a month ago, but they eased later after the release of the soft US Consumer Price Index (CPI) data for June.
Surging oil prices due to risks of a prolonged closure of the Strait of Hormuz and the Bab el-Mandeb Strait, critical chokepoints that are collectively responsible for 27% of global energy supply, have boosted inflation projections, a scenario that forces central banks to advocate tight monetary conditions.
Higher US bond yields have also strengthened the US Dollar. At press time, the US Dollar index (DXY), which tracks the Greenback’s value against six major currencies, trades firmly near the three-week high at around 101.50.
On the domestic front, Australian employment data for June and the flash S&P Global Purchasing Managers’ Index (PMI) data for July have come in stronger.
On Thursday, the labor market report showed that the economy created 76.3K fresh jobs, significantly higher than 44K in May. Earlier in the day, Australian Composite PMI arrived at 52.6, higher than 50.4 in June.
AUD/USD technical analysis
AUD/USD trades marginally higher at 0.6975, hovering right on the 20-period exponential moving average (EMA) at 0.6975, which acts as a pivotal line for the near-term trend.
The pair is consolidating after recovering from late-January lows, and the neutral stance is reinforced by the Relative Strength Index (RSI) holding just below the 50 mark around 49, hinting at balanced but still fragile momentum.
The Aussie pair might see a fresh upside towards 0.7100 if it breaks above the July 21 high at 0.7027. Looking down, the pair would be exposed to the June 30 low at 0.6865 once it breaks below the July 14 low at 0.6913
(The technical analysis of this story was written with the help of an AI tool. Know more.)
Economic Indicator S&P Global Composite PMI The Composite Purchasing Managers Index (PMI), released on a monthly basis by S&P Global, is a leading indicator gauging private-business activity in Australia for both the manufacturing and services sectors. The data is derived from surveys to senior executives. Each response is weighted according to the size of the company and its contribution to total manufacturing or services output accounted for by the sub-sector to which that company belongs. Survey responses reflect the change, if any, in the current month compared to the previous month and can anticipate changing trends in official data series such as Gross Domestic Product (GDP), industrial production, employment and inflation. The index varies between 0 and 100, with levels of 50.0 signaling no change over the previous month. A reading above 50 indicates that the Australian private economy is generally expanding, a bullish sign for the Australian Dollar (AUD). Meanwhile, a reading below 50 signals that activity is generally declining, which is seen as bearish for AUD.
SLB N.V. (NYSE:SLB) will release its second quarter earnings report before the opening bell on Friday, July 24.
Analysts expect the Houston, Texas-based company to report quarterly earnings of 52 cents per share, down from 74 cents per share in the year-ago period. The consensus estimate for SLB quarterly revenue is $8.68 billion. It reported $8.55 billion last year, according to Benzinga Pro.
On July 14, SLB announced an agreement with Liberty Energy Inc. (NYSE:LBRT) to form a strategic alliance for data center infrastructure and power.
SLB shares fell 0.9% to close at $47.22 on Thursday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.
Considering buying SLB stock? Here’s what analysts think:
Photo via Shutterstock
Market News and Data brought to you by Benzinga APIs
Trumpova administrativa zavádí nová cla, v EU jsou z toho překvapeni. Moneta zveřejnila své výsledky a zlepšila výhled, Volkswagen ho naopak zhoršil. Intel začíná čím dál více těžit z datacenter, což se projevuje i na tržbách.
Pokračování článku je dostupné jen klientům placených služeb Patria Plus / Investor Plus případně uživatelům platformy Patria Direct. Pokud jste klientem těchto služeb, potom je nutné se Přihlásit.
V rámci placeného informačního servisu získáte přístup ke kompletnímu zpravodajství www.patria.cz bez jakýchkoliv omezení. Veškeré zprávy, komentáře a horké zprávy jsou zobrazovány terminálovou metodou (bez nutnosti obnovovat stránku) bez zpoždění a v plné verzi.
Nejen zpravodajství, ale i další služby získáte v Patria Plus / Investor Plus - sms a e-mailové zpravodajství, data z finančních trhů v reálném čase, kompletní analytický servis, rozsáhlé databáze časových řad ke stažení, prognózy vývoje a valuace, ekonomické fundamenty, nástroje a kalkulátory... více
